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Abstract 
Diabetes mellitus designates a range of metabolic disorders characterised by 
hyperglycaemia due to deficient or absent insulin secretion, insulin action, or both. In 
particular, Type 1 diabetes is characterised by a total lack of endogenous insulin 
secretion which has to be replaced by exogenous insulin to control the plasma 
glucose concentration. 
An extracorporeal wearable artificial pancreas (AP) has been a research aim for over 
three decades. The research is motivated by the need to improve glucose control. 
Results of a major study, the Diabetes Control and Complications Trial (DCCT), have 
demonstrated that improvements in glucose control prevent or delay long term 
complications, which are the main causes of morbidity and mortality in subjects with 
Type 1 diabetes. 
Prior to a clinical evaluation, performance of new medical devices can be tested in 
silico. Such an approach has been adopted extensively by the pharmaceutical 
industry in the development of new drugs. In silica testing benefits from relatively low 
financial, human, and time costs by comparison with the resources required for a full 
clinical evaluation. 
The aims of the present thesis are to identify components of the AP, integrate them 
into a simulation environment, and design an in silico evaluation strategy for the 
development of closed-loop algorithms with the ultimate goal to assess safety and 
efficacy prior to clinical evaluation. 
In the present work, submodels of metabolic processes were linked to represent the 
characteristics of the glucoregulation in Type 1 diabetes. The submodels were 
associated with sets of parameters to account for variability in population and 
individual responses to meals and insulin therapy. The model of glucoregulation in 
Type 1 diabetes was extended by models of subcutaneous (sc) glucose sensing and 
sc insulin delivery to represent all aspects of the AP. 
A systematic approach was developed and employed to evaluate, in silica, the 
potential and limitations of an AP glucose controller. This was exemplified by 
evaluating a nonlinear model predictive controller. The robustness of the AP was 
explored by hypothesising various perturbations induced by different system 
components. 
A further objective included the establishment of a qualitative grading scheme of 
glucose control from the clinical viewpoint. This was followed by a comparison 
between results from simulations and a clinical trial of 24 hours, which gave the proof 
of concept of in silica testing. It was found that despite discrepancies due to initial 
conditions and meal differences, the simulations indicated well the outcome of the 
clinical trial. 
In conclusion, the thesis demonstrates the significant potential of in silica testing to 
make predictions about system behaviour aiding the assessment of safety and 
efficacy of control algorithms during the development of an AP. 
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Chapter 1: Introduction and Thesis Structure 
1 Introduction and Thesis Structure 
1.1 Background and Motivations 
Type 1 diabetes is a widespread metabolic disease characterised by a total loss of 
insulin secretion resulting in elevated glucose (hyperglycaemia). Exogenous insulin is 
needed to maintain normoglycaemia and to avoid death. The aim of the treatment is 
to limit hyperglycaemia while avoiding low glucose (hypoglycaemia). 
Results from the Diabetes Control and Complications Trial (DCCT) (1) and the United 
Kingdom Prospective Diabetes Study (UKPDS) (2) have demonstrated the 
importance of intensive insulin therapy to achieve better glucose control and to avoid 
or at least delay diabetes complications. Near normal glucose control is difficult to 
achieve requiring patient compliance and a considerable health care infrastructure. It 
is associated with an increased risk of hypoglycaemia (1). 
The emergence of advanced glucose measuring and insulin delivery devices has 
improved self management of diabetes (3-5). The development of new insulins with 
various pharmacokinetic and pharmacodynamic characteristics (6-8) have played an 
important role in the progress toward a more physiological insulin profile (9). 
Education has a major role to play in the improvement of glucose control (10) but this 
implies an effort and compliance which can be difficult to achieve in some subject 
groups such as in adolescents or the elderly. To reduce the burden and to achieve an 
optimum insulin delivery reproducing more closely the physiological insulin release, 
an automated insulin delivery device is therefore desired. 
Approaches to tight glucose control rely on the intensified insulin therapy represented 
by two types of strategy. The multiple daily injection (MOl) consists of three to four 
insulin injections a nd glucose measurements daily ( 11,12) and the use of different 
insulins (fast and slow acting) in attempting to mimic the pancreatic insulin release. 
The second approach employs the continuous subcutaneous insulin infusion (CSII) 
through an insulin pump (11,13,14). Changes in insulin requirements can be handled 
1 
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with more flexibility. This facilitates a closer match to the pancreatic insulin release. 
However, the outcome of the CSII is dependent on user attitudes (15). 
Both approaches are still suboptimal. Several studies illustrate the presence of large 
glucose deviates from the target glucose concentration (16). Periods of 
hypoglycaemia and hyperglycaemia periods can be largely unnoticed. 
Combining a continuous glucose monitor, with an insulin pump controlled by an 
algorithm, an optimised insulin delivery could be achieved in a closed-loop fashion 
(17 -21). For management, costs and safety reasons, the widespread application of 
the artificial pancreas (AP) is likely to employ the subcutaneous glucose 
measurements and the subcutaneous insulin infusion which unfortunately introduce 
considerable delays and variability (22-24). Therefore, the extracorporeal AP is still 
awaiting the solution of a range of issues and especially the development of a 
reliable continuous glucose monitor. 
Safety and efficacy aspects of the AP need to be extensively addressed in a range of 
situations and under different conditions. This represents a high demand for clinical 
testing at a considerable cost. The potential for setbacks is considerable and limits 
the development of such devices. 
Considerable knowledge has been compiled about the characteristics of the whole 
body glucose metabolism and its control by exogenous insulin. Physiological 
modelling enables physiological systems to be described mathematically and 
therefore enables implementation of temporal models on a computer. This suggests 
that the use of glucoregulatory simulators has the potential to accelerate the 
development of the AP and the control algorithm in particular. 
Many studies have focused on the development of a control algorithm for closed-loop 
systems. However, it appears that none encompassed a systematic and complete in 
silica testing. The objective of the project Advanced Insulin Infusion using a Control 
Loop (ADICOL) was to develop a treatment system that continuously measures and 
controls glucose values in subjects with Type 1 diabetes. The modular concept of the 
ADICOL's biomechanical artificial pancreas consisted of a minimally invasive 
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subcutaneous glucose sensor, a handheld PocketPC computer, and an insulin pump 
(Disetronic D-Tron) delivering subcutaneously insulin lispro. The ADICOL project 
demonstrated the feasibility of a closed-loop glucose control during fasting and fed 
conditions with a wearable, modular extracorporeal artificial pancreas. The 
development of a control algorithm for closed-loop control was a critical task of the 
ADICOL project. It became clear that a comprehensive simulation environment was 
needed to support the development of the algorithm. As such an environment was 
not available, the project described in this thesis was initiated as part of the ADICOL 
work. 
1.2 Aims 
The primary aim of the thesis is to facilitate the development of glucose controllers by 
designing, implementing, and validating an in silica testing environment. The 
secondary aim is to develop a methodology to test systematically glucose controllers 
and exemplify its use in the assessment of a model predictive controller (MPC) 
developed in parallel with the simulation environment during the ADICOL project. 
1.3 Objectives 
There are four technical and two clinical objectives. 
1.3.1 Technical objectives 
The technical objectives are 
• To develop a model of the whole body glucoregulatory processes in subjects 
with Type 1 diabetes treated by the CSII; 
• To c reate a population of virtual subjects with Type 1 diabetes representing 
inter and intra-subject variability; 
• To create a simulation environment facilitating testing of an extracorporeal AP 
consisting of a glucose sensor, a control algorithm, and an insulin pump; 
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• To develop a methodology for in silico systematic testing of glucose controllers 
in a simulation environment. 
1.3.2 Clinical objectives 
The clinical objectives are 
• To define clinically relevant criteria to assess glucose excursions during 
closed-loop control; 
• To a ssess clinical validity of the simulator by comparing simulated and real 
clinical trials. 
1.4 Thesis Structure 
A review of diabetes mellitus is given in Chapter 2 starting with a general overview of 
glucose metabolism and then focussing on Type 1 diabetes and the current standard 
treatments are presented. 
Chapter 3 reviews approaches to simulation and modelling in diabetes. Decision 
support systems are also reviewed. This is followed by a review of closed-loop 
control algorithms. A non-linear MPC is described in greater detail as it is used in the 
following chapters to demonstrate the performance of the simulation environment. 
Chapter 4 describes a model of the glucoregulatory processes. The model consists of 
submodels, which are individually presented. 
Chapter 5 describes the simulation environment which includes an insulin pump 
model, a calibration model, and a measurement model. The chapter also describes 
the generation of 18 synthetic subjects with Type 1 diabetes and the approaches 
taken to represent inter- and intra-subject variability. 
The methodology to evaluate glucose controllers In a virtual environment IS 
presented in Chapter 6. 
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Chapter 7 defines clinically relevant criteria for the assessment of glucose excursions 
during closed-loop control and focuses on the clinical validity of the simulator by 
comparing results obtained in the simulated and clinical studies. 
A general discussion is presented in Chapter 8. This is then followed by conclusions 
summarising the achievement of the objectives and outlining future work. 
Appendix A contains Matlab/Simulink® plots of glucose control in synthetic subjects 
controlled by the MPC. 
Appendix B includes Matlab/Simulink® block diagrams representing the model of 
subjects with Type 1 diabetes, and the measurement and insulin pump models. 
Appendix C contains publications. 
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2 Type 1 Diabetes and its Treatment 
2. 1 Introduction 
Diabetes is a widespread metabolic disorder affecting glucose homeostasis and 
characterised by chronic hyperglycaemia (elevated blood glucose). The 
worldwide increase in incidence has enormous cost implications due to the long 
term complications (25). In Sweden in 1994, resources expenditure was three 
times higher to treat complications compared to what was spent on control of the 
disease (26) and accounted for 2% of the total hospital admissions in the US in 
1987 (27). The predictions are alarming (28) with projected 221 million cases in 
2010 against estimated 124 million cases in 1997 (29). 
There exist several types of diabetes but the vast majority is accounted for by 
Type 1 and Type 2 diabetes. The former subgroup is characterised by an 
absolute deficiency in insulin secretion whereas the latter is characterised by a 
relative lack of insulin secretion and/or insulin action. Treatment is essential to 
prevent long term complications but is not easily achieved. 
In this chapter, a general overview of glucose metabolism is presented and is 
followed by the description of the types of diabetes with a focus on Type 1 
diabetes, its treatment and complications. 
2.2 Glucose Metabolism 
2.2.1 Generalities 
Glucose is the primary energy source for the metabolism of cells. Blood 
circulation is its conveyor within the body ensuring its distribution. For some 
organs, in particular the brain, glucose is the only usable substrate. However, if 
glucose is vital, at high concentrations it is also toxic to the cells. In healthy 
people, blood glucose is finely controlled and remains stable at a level normally 
falling in a range of 3.9 to 6.1 mM (30) with a slight transient elevation following 
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meals very rarely exceeding 7.8mM (31) and with a return to normal within two to 
three hours. 
The glucose homeostasis ism aintained through different pathways 0 f glucose 
absorption, endogenous production, utilisation, and storage under the main 
control of antagonist hormones glucagon and insulin. The glucose concentration 
is constantly balanced by glucose appearance and its utilisation by the tissues. 
2.2.2 Systemic Glucose Appearance 
Two sources of glucose contribute to systemic glucose a ppearance. First, the 
endogenous source originates from various organs such as the liver and the 
kidneys. Second, the exogenous source is from the digestion of food. In the 
latter case, the rate of appearance of glucose is dependent on various factors 
such as the type of carbohydrates, meal composition, gastric motility and 
emptying, and intestinal absorption (32-35). 
2.2.3 The Pancreas 
The pancreas is a hook shaped flat organ measunng about 12.5-15cm and 
located behind the stomach. It has both an exocrine and endocrine role. The 
exocrine pancreas secretes the pancreatic juice that aids the digestion while the 
endocrine pancreas through a specialised group of cells constituting the islets of 
Langerhans secretes insulin ＨｾＭ｣･ｬｬｳＩ＠ and glucagons (a-cells). 
2.2.4 Insulin 
Insulin is the predominant controlling factor of plasma glucose (PG). It is a 
hormone made up of two polypeptide chains and secreted by the pancreas 
J3-cells. Insulin has a potent hypoglycaemic and sparing effect. Numerous 
substances inhibit and stimulate insulin secretion but glucose itself has by far the 
most stimulating effect. Other components such as certain amino acids (resulting 
from protein hydrolysis during digestion) and gut hormones known as the 
glucagon-like peptide (GLP-1) and the gluco-dependent insulinotropic 
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polypeptide (GIP) are also involved in insulin release (36,37). It is believed that 
neuromediators (38) have a feed forward effect on insulin secretion. 
Insulin is delivered through the portal vein allowing fast distribution and therefore 
exercises a quick response to elevated plasma glucose. By binding to insulin 
receptors, insulin enables glucose to enter the cells where it is metabolised. 
The glucose uptake by the liver represents about one third of the ingested 
glucose (39) and the liver is the most important organ for postmeal glucose 
uptake in addition to the systemic glucose removal (40). The remaining glucose 
is taken up by an increased glycolysis (transforming glucose into pyruvate), 
glycogenesis (glucose polymerisation into glycogen) in the muscle, and 
increased lipogenesis (synthesis of fatty acids), insulin stimulating triglyceride 
storage in the adipose tissue while glycogenolysis (the production of glucose 
from stored glycogen) and gluconeogenesis (the transformation of pyruvate and 
certain amino acids into glucose) is reduced. 
Although the liver is central to glucoregulation, in terms of glucose storage 
capacity muscles represent a larger reservoir. Of the 500g of carbohydrates 
(CHO) which can be stored as glycogen, 25% are retained by the liver while the 
remaining 75% are retained in the muscle (41). 
When the glucose level is normalised, insulin secretion is strongly inhibited and 
returns to a level controlling the endogenous glucose production mainly driven 
by the hepatic glucose output (42). 
Because of its key role, a deficiency In insulin secretion and/or insulin 
insensitivity will result in a departure from a normal healthy glucose profile. At the 
same time, insulin is not needed at all time and has to be disposed of by the 
body. Most of secreted insulin is degraded by the liver (43), the remaining insulin 
being catabolised by most tissues. 
Some tissues do not need insulin to utilise glucose such as the control nervous 
system and the brain. 
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2.2.5 Glucagon 
The counterregulatory hormones are catecholamine, glucocorticoides, growth 
hormone, and glucagon which have synergic effects but the latter is by far the 
most potent. Glucagon is secreted by the a-cells in response to a low glucose 
concentration and has an opposite effect to insulin. Its role is to preserve the 
glucose concentration constant between meals or during an extended fasting 
period. Numerous factors contribute to the production of glucose to prevent 
hypoglycaemia. Glucagon stimulates glycogenolysis (the glucose production 
from stored glycogen) and gluconeogenesis from pyruvate, glycerol (resulting 
from adipose triglycerides degradation and metabolised by the liver) and certain 
amino acids by series of complex enzymatic reactions. Glycerol can have a 
significant role in prolonged fasting (44) and glycogen from the muscle can only 
be used indirectly by a complex biochemical process producing lactic acid which 
can be converted into glucose by the liver (41). 
Should these first barriers to prevent hypoglycaemia be insufficient, another 
hormone, epinephrine, which is secreted by the adrenal medulla (41), can 
quickly contribute to a glucose rise. 
2.2.6 Conclusion 
In healthy people, glycaemia is principally maintained through the antagonist 
insulin/glucagon hormone actions. The liver is set into an uptake or storage 
mode by insulin and when glucose concentration drops, glucagon stimulates 
glucose production from stored glycogen and through glycogenesis and 
gluconeogenesis processes. In Type 1 diabetes mellitus, a metabolic disorder 
characterised by hyperglycaemia, insulin not secreted and needs to be replaced 
by exogenous inputs to regulate glucose storage and utilisation. 
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2.3 Diagnostic Categories 
2.3.1 Type 1 Diabetes Mellitus 
Type 1 diabetes is characterised by absolute deficiency of insulin secretion and 
was for this reason previously called insulin dependent diabetes mellitus or 
100M. 
Type 1 diabetes is usually diagnosed at an early age, most commonly under 20 
years. Its prevalence is characterised by a large geographical variation with 
about 30 cases per year per 100 000 of the population in Finland down to 0.5-2.0 
cases per year per 100 000 of the population in Japan (45) strongly suggesting 
ethnic and environmental factors. Moreover, a seasonal variation seems to be 
present. 
Type 1 diabetes IS believed to be an auto-immune disease in which the 
pancreatic f1-cells are perceived as a foreign body and are destroyed by the 
immune system. 
Symptoms include frequent thirst and urination, blurred vision, weight loss and 
hyperphagy. Diagnosis is critical as elevated glucose can lead to coma and 
death. 
2.3.2 Type 2 Diabetes 
Type 2 diabetes is also characterised by wide differences in its prevalence 
ranging from less than 1 % in Mapuche Indian, Chile, to about 50% in Pima 
Indian, USA (45). In developing countries it represents almost 100% of the cases 
and represent a large number of newly diagnosed diabetic subjects in developed 
countries (46,47). 
Type 2 diabetes is characterised by a relative lack of insulin secretion and 
sensitivity. Insulin deficiency is due to failing of the r1-cell to secrete enough 
insulin which is needed in a greater quantity to compensate for the insulin 
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resistance associated with Type 2 diabetes. Type 2 diabetes is very insidious 
and can develop over years before being diagnosed. It is usually found in people 
over 40 years old, a decade earlier in newly westernised countries and accounts 
for the majority of diabetic cases representing about 97% of the population 
affected by the disease worldwide (29). The rate of increase is epidemic and it 
already affects more than 150 million persons. 
It is believed that the origin of type 2 diabetes is multifactorial. These include a 
sedentary life style, obesity, and some nutritional related factors. Most common 
symptoms include thirst, urination, and tiredness. 
2.3.3 Other Types of Diabetes 
Gestational diabetes mellitus is characterised by glucose intolerance occurring 
during pregnancy, in most case reversibly. It is estimated that it affects 135,000 
pregnant woman annually in the U.S.(30). 
Various genetic defects can lead to diabetes. Some affect the ｾＭ｣･ｬｬ＠ function 
resulting in reduced insulin secretion, other affect insulin action mostly because 
of a genetic defect of the insulin receptor. 
Partial or total pancreatectomy can also induce a relative or total lack of 
endogenous insulin secretion inevitably resulting in diabetes. 
Lastly, some drug and chemicals can induce diabetes by Impairing insulin 
secretion or insulin action. Contact with certain toxins or medications will induce 
diabetes with a variable severity. 
2.4 Type 1 Diabetes 
The focus of the present work is on subjects with Type 1 diabetes, a much less 
common form than Type 2 diabetes but still highly prevalent in the developed 
countries. Type 1 diabetes accounts approximately for 10-15% of diabetes cases 
in developed countries (48) and is the most common chronic disorder in children. 
1 1 
Chapter 2: Type 1 Diabetes and its Treatment 
The exact cause of Type 1 diabetes is not fully understood but aetiological 
studies suggested risk factors including genetically mediated hereditary factors 
(49). Several genes are implicated in an increased susceptibility to develop 
diabetes. Particularly strong associations have been found with the human 
leukocyte antigen (HLA) DR3 and/or DR4 present in 95% of Caucasians with 
Type 1 diabetes (45). 
In most cases, Type 1 diabetes is the result of an autoimmune disorder causing 
the subject's immune system to attack its own tissues. More specifically, in the 
case of Type 1 diabetes the immune system targets the pancreatic ｾＭ｣･ｬｬｳ＠ which 
secrete insulin. Several antigens have been implicated including islet cell 
antibodies (ICA) and glutamate decarboxylase (GAD), the latter being present in 
a majority of recent onset Type 1 diabetes subjects (45). 
Several nutritional factors are also suspected to induce Type 1 diabetes, in 
particular the milk proteins, but this still lacks solid evidence (50). An exposure to 
certain infections is also suspected to trigger an autoimmune reaction (51) and 
infant's day-care seems to playa role in the incidence of diabetes (52). Other 
possibilities include physical injuries, pancreatectomy, or contact with specific 
toxins. 
2.5 Diabetic Complications 
If glucose is vital to the cells, an excessive glucose concentration is also toxic 
and leads directly or indirectly to a large panel of complications with huge cost 
implications. In 1997, the United States health care expenditure for diabetes was 
about 15% of the total budget of which 95% were associated with diabetes 
complications. 
Complications fall into two categories, acute complications, that develop quickly, 
and chronic complications also qualified as long term complications. 
The acute complications are due to large deviations from normoglycaemia. 
These include hypoglycaemia and severe hypoglycaemia usually defined as 
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plasma glucose below 3.3 and 2.BmM, respectively, and hyperglycaemia when 
plasma glucose is above the level of 13.9mM. 
Although not due to diabetes itself but ironically to its treatment, the most 
immediate complication is a drop in plasma glucose due to an oversupply of 
insulin. This can happen in a number of situations, most commonly, due to an 
overestimated insulin bolus at the meal time, or an unexpected alcohol intake, or 
exercise. 
A large insulin excess leads to pronounced hypoglycaemia, and possibly death. 
Fortunately, in most cases the subject will experience symptoms which can be 
autonomic (due to the body reaction to hypoglycaemia) or, if plasma glucose 
further decreases, neuroglycopenic (due to the brain glucose deprivation). 
However, it has been reported that repeated hypoglycaemia can diminish 
hypoglycaemia symptoms and couterregulation, resulting in a condition known 
as hypoglycaemia unawareness (53,54). 
Acute hyperglycaemic complications correspond to diabetic ketoacidosis (DKA) 
and hyperosmolar hyperglycaemia. Although not as immediate as 
hypoglycaemia, DKA is a serious condition and may cause death among 
subjects with Type 1 diabetes. DKA is the result of a build up of catabolic 
by-product in the blood stream due to shortage of insulin. 
Chronic hyperglycaemia is responsible for tissue damage. The long term 
complications can be grouped into the microvascular and macrovascular 
complications. 
The microvascular complications affect the retina. Retinopathy is induced by 
vasopermeability and non perfused areas. At an advanced stage this results in 
haemorrhage and severe ischemia responsible for a non-reversible vision loss. 
Nephropathy is another common microvascular complication. It affects various 
parts of the kidneys. This condition is well characterised by an increased 
capillary pressure and protein leakage. Ultimately, a major dysfunction and 
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kidney failure will occur. Subjects survival is then subject to renal replacement 
therapy. 
Neuropathy IS another type of long term microvascular complication. It is 
responsible for a large number of non traumatic amputations. As opposed to 
retinopathy and nephropathy, this complication affects various organs of the 
body by damaging the nervous system. A foot ulceration and neuropathic 
oedema are some of the most common occurrences due to neuropathy. Other 
complications related to the nervous system damage include gastroparesis, 
diarrhoea, neuropathic bladder, erectile failure, and anomalous cardiovascular 
reflexes. 
The second family of long term complications involves large blood vessels. It is a 
leading cause of cardiovascular disease in diabetes subjects. Because of the 
aetiology of Type 2 diabetes this family of complications is more frequent in Type 
2 diabetic subjects because these often pre-exist and constitute the background 
for the development of the disease. However, poorly controlled subjects with 
Type 1 diabetes are also affected because of the high level of the plasma insulin 
concentration combined with high plasma glucose at other times. 
Lastly, subjects with diabetes are more prone to infections. Combined with a 
decreased sensation, this can lead to pain free ulcer which then can possibly 
lead to amputation. 
2.6 Standard Diabetes Treatment 
Insulin was discovered in the early 1920s. Before then Type 1 diabetes led to 
death as insulin is the only hypoglycaemic agent in the body. The hypoglycaemic 
effect of insulin has no redundancy and is still the only available treatment. 
To avoid short and long term complications, subjects with Type 1 diabetes need 
to self inject insulin with the aim to match their insulin needs. The principle is 
simple but the insulin therapy adjustment is in practice very complex explaining 
in part the difficulties for a closed-loop system. 
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An early treatment offered very crude means to control blood glucose. Relying 
on urine glucose strip, it was lacking precision and reliability. At high plasma 
glucose concentration, glucose passes into the urine but the urine test 
measurements do not reflect the plasma glucose concentration. It is influenced 
by a variable dilution. 
In healthy subjects, glucose IS constantly monitored and insulin release is 
constantly adapted to the needs. The objective of the treatment is to replace the 
absence of endogenous insulin by exogenous insulin. Ideally the insulin injection 
should reproduce basal and postprandial insulin profiles. At present, the two 
most common types of treatment are based on multiple daily injections (MOl) or 
the continuous subcutaneous insulin infusion (CSII) using an insulin pump. 
Three main insulin types are now available: long, intermediate, and fast acting 
insulin analogues. These provide a different onset, peak, and duration of action 
(6,8,55-57). 
2.6.1 Multiple Daily Injections 
Treatment with multiple daily injections (MOl) is the most commonly employed 
approach to control blood glucose in Type 1 diabetes. 
The strategy of the MOl treatment is to use insulin with various time action 
profiles to reproduce the basal rate with long and intermediate acting insulins 
and the postprandial insulin surge with fast acting insulin (58). The long acting 
insulin is, ideally, a slow, peak-free insulin (59,60) mimicking the basal needs. 
The fast acting insulin is quickly absorbed with an early peak action (61). 
With the multiple daily injections, two types of treatments have been developed 
making use of the insulin characteristics by combining fast acting and 
intermediate acting insulins or mixing long acting and fast acting insulins. 
The conventional therapy consists of two injections per day with intermediate 
and fast acting insulin given at breakfast and in the evening. The aim is to avoid 
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symptomatic h yperglycaemia a nd severe h ypoglycaemic episodes. The insulin 
regimen is dictated by the subject's lifestyle and finger prick glucose 
measurements. 
Another type of insulin treatment is called the intensive therapy. It has gained 
popularity and is widely promoted because of its superior results compared to 
the conventional therapy (1,62). It consists 0 f a mixture of long, intermediate, 
and fast acting insulin but the difference lies in the more tailored approach than 
that adopted by the conventional therapy. It consists of a minimum of three 
injections per day. Insulin is injected before each meal in addition to long acting 
insulin which covers the basal needs. 
Combined with educational training, the intensive therapy leads to improved 
treatment (10) and enhanced life quality (63). 
The improvement in insulin therapy has been made possible thanks to a 
progress in insulin engineering but also in the availability of reliable and 
easy-to-use monitoring devices (64). Measurement devices are numerous and 
have become more and more advanced often keeping track of past events 
therefore facilitating optimisation of insulin treatment and helping in the adoption 
of the intensive insulin therapy. 
Injections classically rely on syringes but devices known as insulin pens facilitate 
the insulin administration by combining an insulin cartridge with a highly 
pressurised air mechanism. Their usage characteristics have promoted their 
dissemination and improved self care (65). 
The main objective for glucose control is individually tailored insulin delivery. An 
approach employing a continuous infusion of fast acting insulin is increasingly 
used because of its numerous advantages to provide an improved insulin 
delivery. This is presented in the next subsection. 
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2.6.2 Continuous Subcutaneous Insulin Infusion 
The continuous subcutaneous insulin infusion (CSII) is seen as an alternative to 
MOL CSII dates back to the late 1970s with the first report of a portable insulin 
pump (66). Initially very bulky, burdened by a limited battery life and insulin 
aggregation, insulin pumps have became popular during the last ten years (67). 
They have the size of a pager, equipped with a long-life battery and far more 
stable insulin. 
As opposed to MOl, during CSII insulin is infused continuously with a 
pre-programmed user-defined profile and an additional bolus at meal time. This 
provides for a more regular insulin delivery facilitating a more physiological 
plasma insulin profile. 
There are two types of insulin pumps, either internal, delivering insulin 
intraperitonealy but requiring surgery to be implanted, or external, employing the 
subcutaneous delivery route and being minimally invasive. External pumps have 
entered into routine use. The use of internal pumps is limited and the present 
section focuses on external pumps. 
An advantage of insulin pumps is related to the use of fast acting insulin 
permitting fast changes in the plasma insulin profile. This allows f or a greater 
flexibility to adapt to the subject's lifestyle. 
The downside of the use of fast acting insulin is an increased risk of 
hyperglycaemia and ketoacidosis. Because of its short-term action, an insulin 
infusion discontinuation will lead to hyperglycaemia faster than with regular 
insulin (68-70). However, pumps can be equipped with a pressure sensor to 
detect occlusion (71). However, complications are due to the catheter dislocation 
or a possible mechanical failure. This risk implies frequent measurements and a 
more extensive education of pump users (68). Studies have shown that fast 
acting insulin lispro is safe and an insulin of choice for pumps (71). 
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Many studies have demonstrated the association between a good glucose 
control and the reduction of the long term complication (62,72-75). Some studies 
focused on comparing MDI and CSII in terms of efficacy and safety (13,76). 
Results shown some improvements in metabolic control (77,78) but also an 
improvement in the number of hypoglycaemia events (13,79,80) usually 
associated with the tight glucose control. 
CSII has been shown to improve insulin sensitivity (78) which is important 
because of the deleterious effect of excessive insulin delivery needed in the 
insulin resistant patient. Insulin has been associated with weight gain which in 
turn increases the risk of complications. A relatively low weight gain has been 
reported in a review by Bode et al (67). 
With CSII, an insulin sensitive subject can benefit from a high resolution of 
insulin delivery, usually as low as 0.1 U/h which is not possible with the MDI 
approach. CSII can enhance the control of subjects expenenclng 
hyperglycaemia due to the dawn phenomenon (81). 
CSII is ideal for some but not for all. An important factor for the choice of a pump 
is related to the subject's compliance. A meal content estimation and regular 
monitoring are a requirement for a successful and safe pump use. Despite its 
advantages, the adoption of the insulin pump can be slowed down by its initial 
cost and an expensive maintenance (82). 
2.6.3 Other Insulin Delivery Approaches 
Other types of insulin delivery are under development. Iontophoresis can be 
employed to deliver insulin by circulating an electric current provoking the 
migration of insulin molecules through the dermal route (83,84). 
Inhaled insulin is being investigated (85-88). The pulmonary delivery route 
presents appealing properties such as convenience, non-invasiveness, and the 
speed 0 f absorption (85). However, a I arge a mount of insulin is not absorbed 
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(87) and clearance mechanisms are still unclear. But progress is being made 
(86,88). 
Other controlled release approaches are being elaborated employing various 
materials. Biocompatible and biodegradable materials such as hydrogel (89,90) 
or microspheres (91-93) could be employed. 
A large amount of work has been devoted to pancreatic transplantation (94-97). 
The first transplantation was performed in the 1960s. This treatment can offer a 
full normalisation of glycaemia but its use is limited by the availability of sources 
of the pancreatic cells and requires a lifetime of immunosuppressive treatment 
(98) which is known to weaken the immune system. 
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3 Simulation and Modelling to Support Treatment of 
Type 1 Diabetes 
3. 1 Introduction 
Glucoregulation is an extensively studied system. Over the last three decades, 
different approaches have been applied to distil complexities and intricacies of 
the glucose metabolism on the whole body, organ, or cellular level. 
The present review is concerned with modelling and simulation of the 
glucoregulatory system on the whole body level. Specific subsystems are also 
reviewed. A review of model-based decision support systems is also included. 
The focus is on approaches related to Type 1 diabetes. Models describing insulin 
secretion are therefore excluded. Finally, a review of closed-loop approaches to 
treat Type 1 diabetes is presented. A non-linear model predictive controller is 
described in detail as it is used extensively throughout the thesis to exemplify the 
utility of the simulation environment. 
3.2 Modelling of Glucose Metabolism 
Modelling and simulation of the glucoregulatory system has a long history as a 
tool to explain, quantify, predict, and teach. As all models have a restricted 
validity, their use has to be limited to a specific domain. By definition, a model 
can only be an approximation of the system behaviour. However, it can be 
sufficient for its intended purposes. 
A large proportion 0 f models to represent the glucoregulatory system adopt a 
compartmental approach which offers suitable means to describe fluxes between 
different body organs and/or tissues in terms of the mass balance expressed in a 
mathematical form. 
Simple models have been proposed by Cobelli et al (99-101), resorting to a 
single compartment model. These models require assumptions which are not 
fully compatible with the glucose system. Others have also adopted simple linear 
models leaving out many of the non-linearities present in the physiology such as 
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saturation processes (102). Specifically, Ackerman et al (103) introduced one of 
the first models to represent glucose and insulin kinetics employing two linear 
differential equations. This two compartment model had two parameters for the 
glucose kinetics and two parameters for the insulin kinetics. 
More complex structures were proposed by Cerasi et al and Insel et al 
(104,105). A three compartment model was proposed by Ferrannini (106) 
representing the distribution and exchange of glucose among the different body 
pools. However, the representation failed to partition the peripheral and hepatic 
glucose disposal. 
Salzsieder et al (107) developed a model-based system to optimise the insulin 
therapy. The model was described by fourth-order differential equations. The 
approach consisted of identifying subject's metabolism characteristics, and 
employed simulations to derive an optimised insulin therapy. 
A study by Boroujerdi et al (108) focused on representing glucose transport 
processes. This explanatory model was employed in various simulations to 
increase our understanding of glucose utilisation in subjects with diabetes. The 
model included insulin dependent and independent glucose disposal and a 
glucose saturable flux into the intra cellular space. 
New technologies such as the positron emission tomography (PET) combined 
with the use of tracers have enabled to increase our understanding and 
knowledge. The technique has provided deep understanding of glucose 
transport leading to a 15 compartment model (109). 
In line with a detailed description of the glucoregulatory system, Guyton et al 
(110) resorted to a set of 32 differential equations. This model was further 
expanded by Sorensen (111) and included additional components such as the 
glucose counteregulation and disturbances such as meal and exercise. 
Structurally complex models are useful for their explanatory powers. But they 
require complicated experimental methods to derive subject specific parameters. 
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At times, it is important to reduce model complexity and thus the number of 
parameters while retaining the representation of the fundamental physiological 
processes. The primary advantage of the so called "minimal model approaches" 
is that they facilitate the parameter estimation of individual subjects without 
excessively complicated clinical tests. 
Two widely used clinical experiments can be used to estimate characteristics of 
the carbohydrate metabolism using model-based techniques. These tests are (i) 
the intravenous glucose tolerance test (IVGTT) and (ii) the meal tolerance test 
(MTT) or the oral glucose tolerance test (OGTT). 
In 1979, Bergman et al (112) adopted a minimal approach to derive insulin 
sensitivity (S,) and glucose effectiveness (SG) from data collected during the 
IVGTT. Insulin sensitivity describes the ability of insulin to stimulate glucose 
disappearance and glucose effectiveness describes the ability of glucose to 
promote its own disappearance. However, unlabelled IVGTT could not 
distinguish between the glucose production and the glucose disposal. This 
limitation was overcome by developing labelled IVGTT. The minimal model of the 
glucose kinetics (113-115) during the labelled IVGTT facilitates the estimation of 
the hepatic glucose production during the IVGTT. 
As opposed to the IVGTT which can be considered unphysiological, other more 
physiological tests were employed to characterise a subject. Recently, Breda et 
al (116) have employed the oral glucose tolerance test to derive indices of insulin 
secretion and insulin action for a particular subject. An insulin secretion model 
during the MTT by Hovorka et al (117) gives indices describing the ability of the 
pancreas to secrete insulin under fasting and postprandial conditions. 
A number of models (110,118,119) have been adopted in simulation studies 
(120-124) according to particular requirements. These models were employed to 
test control or advisory algorithms and strategies to optimise insulin therapy 
(124-129). 
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A simulator has incorporated the sUbcutaneous insulin kinetics and allowed 
experiments with various insulin inputs and the resulting glucose profile to be 
executed. The simulator was only valid for an average subject (130). Lehmann 
and Deutsch have extended the capabilities of the system by including a 
parameter estimation process. However, the parameter individualisation process 
was not evaluated (131). 
The relationship between plasma and interstitial fluid glucose has been 
investigated following the availability of minimally invasive or non invasive 
subcutaneous glucose sensors (23,132-134). A model of the subcutaneous 
glucose kinetics has been recently developed (64,135,136). Wilinska ef al 
proposed 9 models. Important findings about the temporal variation in interstitial 
glucose (IG) to plasma glucose ratio were found. The study provided background 
information for the new model implemented in the simulator; 2 of the 9 models 
were used in the simulator as described in Chapter 4. 
Modelling studies identified the importance of the insulin delivery route and 
algorithms (137,138). Cobelli ef al (138) employed a previously developed model 
of glucoregulation (118) replacing endogenous insulin secretion by a controlled 
insulin delivery in the liver or plasma compartment. It outlined and explained the 
potential and limitations of the peripheral insulin and hepatic delivery route (138). 
To model the absorption and kinetics of different types of insulin, compartmental 
modelling has again been widely used. A two compartment model representing 
plasma glucose and the interstitial glucose space was developed for actrapid 
(139), a fast acting insulin. A three compartment model was developed by 
Puckett ef al to model the kinetics of human insulin given as boluses (140). 
Another three compartment model dividing the subcutaneous space into two 
subcompartments was developed to describe the kinetics of fast acting insulin 
(141 ). 
The kinetics of insulin Lispro, which is used in insulin pumps, have been 
modelled using a three compartment structure employing bolus injection and 
used for the development of a closed-loop insulin delivery device (142). A model 
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of monomeric insulin was developed by Trajanoski et al (143). The study 
suggests that a change in the absorption rate was not influenced by the varying 
volume and the injection depth. The model was then used in simulations to test a 
glucose controller (124). 
Stimulated by the need for a better therapy, some models were placed in a 
simulation framework. These simulators were used in various ways to educate 
subjects with diabetes or to test 0 pen loop a nd/or closed-loop insulin delivery 
systems. 
Models in simulators developed for educational purposes are usually 
characterised by a representation of an average subject. Therefore these 
systems do not provide individualised advice but rather enable the influence of 
different insulin regimens, meals, or exercise to be understood. 
An educational simulator was developed using a heuristic model of physician's 
predictions (144) to derive the glucose profile from insulin injections In an 
average subject. It included the influence of food intake and exercise. 
In Glucosim (138), a complex model is employed to describe the glucoregulation 
in subjects with Type 1 diabetes representing the glucose kinetics and the 
pharmacokinetics of subcutaneous insulin. Glucosim can be employed to 
simulate virtual experiments. However, the model does not support an 
individualised insulin optimisation. 
An Interactive Diabetes Advisor (AIDA) (145-147), one of the most promoted 
simulators dedicated to education, contains a model that represents both 
endogenous and exogenous glucose inputs. Although AI DA is limited by its 
representation of an average subject, the glucose utilisation is well described by 
distinguishing between the insulin independent and insulin dependent 
components. 
Another approach to modelling adopts the representation of the inpuUoutput 
relationship without attempting to represent explicitly the physiological 
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knowledge. A typical example can be found in a published simulated study by 
Sano (148) who related the intravenous insulin infusion and the blood glucose 
level using a linearised model. 
The model by Ackerman et al (103) which adopted the input output relationship 
representation was modified to represent a subject with Type 1 diabetes by 
setting the insulin response parameter to zero. It was used in simulated studies 
(127) to obtain knowledge about insulin therapy. 
Parker et al (122) employed a pharmacokinetic-pharmacodynamic approach by 
using a fundamental model by Sorensen. 
A two-compartment model of carbohydrate metabolism has been recently 
developed (42). It provides novel information about certain characteristics of the 
glucose/insulin kinetics. In particular, the study using glucose tracers has 
enabled the partitioning of three different insulin effects on the glucose 
transport/distribution, disposal, and hepatic glucose production. 
In summary, modelling and simulation have complementary aims and may use 
different approaches and reach different levels of complexity. Key elements 
when building a model are to define its objectives and the type and complexity of 
its structure. 
3.3 Decision Support Systems 
Decision support systems are intended to help in the decision making process 
and are used in a wide range of systems, tools, technologies, and domains such 
as in economics for risk analysis, management of various organisational 
processes, or in medicine to facilitate diagnosis, treatment optimisation, or 
disease management. 
In Type 1 diabetes, numerous decision support systems have been employed to 
aid in the optimisation of insulin therapy. A wide variety of approaches for data 
analysis and feature extraction have been employed such as time series 
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analysis (149,150), fuzzy logic (151-153), and causal probabilistic networks 
(154-157). The systems give advice on insulin dosing on a visit-to-visit, 
day-to-day, or dose-by-dose basis depending on the exact objectives. Decision 
support systems in diabetes are numerous but a few stand out. 
In Utopia, the time series analysis technique of subject specific data was 
employed (150) to adjust insulin regimen on a visit-to-visit basis through the 
establishment of a subject's modal-day which implied a certain consistency 0 f 
the subject's lifestyle. 
Hovorka et al (158) developed a model-based system, which employed 
individualised parameter estimation using past glucose measurements and 
insulin administration to generate advice on insulin therapy. The system was 
shown to improve glucose control. 
A diabetes advisory system (DIAS) (157) is a decision support system which 
employs a causal probabilistic network model of the glucose metabolism and the 
Bayesian parameter estimation to predict the glucose profile from historic plasma 
glucose measurements, food intake and insulin doses. 
Others adopted a rule-based approach, see for example Skyler et al (159). 
Diabetex (160) is a knowledge-based system that can accept various modes of 
insulin delivery. However, it has poor capabilities to individualise treatment. 
Stadelmann et al (161) have extended Diabetex with a decision module to take 
into account special situations. 
A mathematical model of the glucose/insulin interactions was used in the 
development of the decision support system Kadis (162). However the 
parameter estimation procedure requires numerous clinical experiments which 
render its extensive use difficult. 
The 0 bjectives 0 f the decision support systems a re different from these 0 f an 
automated closed-loop system. They should not be regarded as a substitute but 
rather complementary to the treatment process. 
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3.4 Closed-Loop Control 
The development of an "artificial endocrine pancreas" for subjects with Type 1 
diabetes has been subject to extensive research since the 1970s. Considerable 
research has been dedicated to the development of insulin delivery algorithms to 
close the loop. Several approaches have shown promising results under 
simulated conditions but few results are available about their clinical 
performance. 
The present review covers the main control strategies developed for a 
closed-loop system. The approaches can be divided into three categories 
according to the type of control employed to drive the insulin delivery: (i) 
non-adaptive approaches, (ii) adaptive or optimal control approaches, and (iii) 
model predictive approaches. 
3.4.1 Non Adaptive Approaches 
These control approaches have the advantage of being relatively simple but are 
limited in their ability to cope with the variability and delays. 
The initial work was carried out by Pfeiffer et al (163) developing the glucose 
controlled insulin infusion system (GCIIS) leading to the development of the 
"Biostator" (164,165), one of the most well known feedback control system still in 
use in experimental settings. The system employed ex vivo blood glucose 
measurements and the intravenous insulin infusion. It used a proportional 
integral derivative (PID) controller coupled with measurement noise rejection 
techniques. The insulin infusion was linked to the rate of glucose change by an 
algorithm developed by Albisser et al (166) with modifications, for example, by 
Botz (167), Marliss et al (168), and Kraegen et al (169). These and similar 
algorithms were reviewed by Broekhuyse et al (170), who concluded that none of 
the algorithms was superior and that further work was required to achieved 
normalisation of the glucose concentration. 
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Another method was developed to close the loop (171). The intravenous insulin 
infusion was modified on hourly basis according to hourly plasma glucose 
measurements. Good control was obtained overnight. The overall amount of 
insulin given intravenous and insulin delivered by an insulin pump via the 
subcutaneous route on the basis of a 4 to 5 days insulin requirement study were 
strongly correlated. The nocturnal basal insulin requirements remained constant 
for several months apart from special conditions such as illness. The authors 
concluded that insulin infusion rates need to be customised to the individual. 
3.4.2 Adaptive and Optimal Control Approaches 
Due to the presence of the inter- and intra-subject variability, optimal and 
adaptive control approaches characterised by the ability to adapt to new 
circumstances are appealing. 
Advanced algorithms used, for example, include the pole-placement technique 
(125). A similar concept was adopted by Shichiri et al (17,172). The optimal 
control theory was employed by Swan (173), Ollerton (174), and Fisher and Teo 
(127). 
A study was carried out focussing on robustness to deal with parameter 
variations and uncertainty using the H-infinity theory but made the assumption of 
the continuous plasma glucose measurement (120). The H-infinity theory was 
shown to provide a good compromise between the performance and robustness 
requirements. However, in another study using the same approach (175), it was 
concluded that the uncertainty needed to be well characterised and it was 
necessary to restrict the uncertainty included on the eight parameters problem to 
that associated the three most highly sensitive parameters. 
Self-tuning controllers were tested under simulated conditions. Self tuning 
controllers are a special group of controllers in which the parameter estimation 
procedure is performed automatically. Such approaches used the subcutaneous 
glucose measurements and the subcutaneous insulin infusion or the peritoneal 
insulin administration (176), and the intravenous glucose measurement and the 
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intravenous insulin infusion (121). Results were promising demonstrating 
insensitivity to variable subject responses but the development did not progress 
beyond the simulation stage. 
Candas and Radziuk (129) employed a similar approach but the aim was to 
maintain euglycaemia with exogenous insulin and glucose infusions. The 
performance of the controller was evaluated in an animal study (three pigs were 
studied) and plasma glucose stability was documented. It was concluded that a 
model mimicking the glucoregulation provided valuable information for the 
development of an artificial pancreas. 
Adaptive control was employed along a finite preview optimal control law ina 
simulation and animal study using a linearised model (177). The intravenous 
measurements with a small dead time of 4 minutes and intravenous insulin 
infusion were used. The adaptive component was beneficial to control 
adjustments due to inter-subject variability. The preview component had a 
positive effect but had to be carefully chosen to avoid hypoglycaemia prior to the 
glucose load. 
3.4.3 Model Predictive Approaches 
Model predictive control ( 178) is an emerging methodology known to facilitate 
control of systems with long time delays and open loop characteristics. 
The strategy of model predictive control is shown in Figure 3.1 (179). Based on a 
model, the output trajectory y(t + kit), k=1 ... N, is estimated for any given control 
sequence u(t + kit) over a prediction horizon N. The model primary use is to 
determine optimum control sequence, which results in a desired (target) 
trajectory. 
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u(t+klt) 
prediction horizon N 
t-1 t t+1 t+k t+N 
Figure 3. 1: Strategy of model predictive control. 
The control action is the first insulin infusion rate u(t+1) of a control sequence 
u(t+1) ... u(t+N), which is calculated by minimising an objective function 
composed of two components, (i) the adherence of the predicted glucose to the 
target trajectory y(t+i) and (ii) the variation in the control sequence. 
The first generation of control approaches was designed for intravenous glucose 
sampling and intravenous insulin infusion. The subcutaneous delivery of insulin 
is less invasive than the intravenous insulin delivery and is suitable for the use 
with a wearable extracorporeal artificial pancreas. 
It has been well recognised that the subcutaneous insulin delivery poses 
problems to efficient glucose control due to the additional delay associated with 
the absorption of subcutaneously infused insulin (138) and only with the 
availability of fast-acting insulin (57,180), the next generation of control 
algorithms could have been developed. When combined with adaptive 
capabilities, model predictive control promises to tackle successfully problems 
associated with control of glucose concentrations in subjects with Type 1 
diabetes. Algorithms developed with such an approach assume a model 
representation of the underlying system and, usually, the model adopts a 
linearised version of one of the many models of the glucoregulatory system 
(80,130,181,182). 
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An early study using the intravenous glucose measurements and the intravenous 
insulin infusion route in dogs pointed out the potential 0 f t he model predictive 
control by comparing a simple glucose projection technique with the direct 
control. A sparing effect on the insulin administration was found (166). This 
represents an advantage over the Biostator algorithm, which tends to administer 
too much insulin and generates spikes because of the derivative component in 
its control law. 
More advanced predictive control schemes were employed later. For example, 
Lynch and Bequette (183) and Parker et al (122,122) have recently used model 
predictive control but limited its use to simulations. In the latter study, good 
results were obtained for measurement delays less than 10 minutes. A 
preliminary identification of each subject had to be performed. A non-linear 
predictive control with subcutaneous insulin infusion using neural networks was 
proposed by T rajanoski et al (123,124). The approach has been evaluated in 
simulated studies. The results confirmed the limitations due to the delays but 
have provided insights into the performance of the closed-loop when minor 
fluctuations of blood glucose are present, e.g. in the preprandial state. The 
authors recommend additional information, e.g. timing of meals, to be provided 
to such algorithms when the subcutaneous-subcutaneous route is considered. 
3.4.4 Non-linear Model Predictive Controller 
In parallel with the work described in the thesis, a new nonlinear MPC has been 
developed to maintain normoglycemia in subjects with Type 1 diabetes 
(184,185). The controller employs a novel non-linear model of the glucose 
kinetics based on a detailed dual-tracer study by Hovorka et al (42). The 
controller adopts Bayesian parameter estimation to facilitate adaptive behaviour. 
The controller is designed to work with subcutaneous measurements and 
subcutaneous insulin infusion. Its structure is presented in Figure 3.2. The model 
predictive controller is used in Chapters 6 and 7 to demonstrate the use of the 
simulator described in the thesis. The two applications were developed hand in 
hand. The simulator assisted in tuning and testing the MPC, the MPC supported 
the assessment of the simulator validity, see Chapter 7. The MPC is described in 
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a greater detail in the present section to facilitate conceptual understanding of its 
structure and functions. 
The MPC controller is designed to be used with subcutaneous glucose sampling 
and subcutaneous infusion of insulin Lispro by insulin pump. In principle any 
glucose sampling/control frequencies, equidistant or non-equidistant, are 
possible without changes to the controller design. 
The model gave glucose predictions with a mean square error proportionally 
related to the prediction horizon with the value of O.2mM per 15 min. 
The block diagram of the controller is shown in Figure 3.2. The controller 
includes t he following components: parameter 0 ptimiser, target p rejector, dose 
optimiser, and safety schemes 1-4 . 
Learning • n Target I Projector 
..... _------. 
Target .... __ ........ 
· 
Trajecory 
· · 
· 
Parameter 
· · 
Dose 
· · · · SC Insulin 
· 
Optimiser · Individual · Optimiser · 
· · · · 
Switch Switch Infusion 
· · 
Parameters 
· · ｾ＠ ......................... ._- .. --_ ...... ｾｾ＠, ......... _.-. ..... _ ............. 
· · · 
· Model 
· 
Model 
· 
· · 
I---
· 
· · · 
· .. .. .. .... .... .. .. .. .. .. . 
......................... 
Basal Minimum 
Dose Dose 
Calculated Ｍｾ＠
Basal Dose Safety Safety 
Scheme 1 Scheme 2-4 
Figure 3.2: Block diagram of the model predictive algorithm. 
Type 1 
Diabetes 
Subject 
f-----1 
Glucose 
measurement 
The parameter optimiser estimates model parameters employing glucose 
measurements from a "learning window", i.e. a time period immediately 
preceding the control time. Three lengths of the learning window are predefined, 
fast, medium, and long, to be able to deal with both a time-invariant (or slowly 
varying) underlying system, which is best identified over a long learning window, 
and a time-variant system best identified over a shorter learning window. 
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The dose optimiser calculates a sequence of insulin infusion rates, which gives 
best fit to the target trajectory. From this sequence, the first element is returned 
and is suggested to be infused by the insulin pump. The remaining elements in 
the sequence are discarded. The dose optimizer adopts non-linear function 
minimisation as the underlying model is non-linear. 
The target projector calculates target trajectory, i.e. the desired glucose profile. 
The target glucose concentration is 6.0mM. When starting above the target 
value, the target trajectory is linearly declining with a maximum decrease set to a 
conservative value of 2mM per hour to reduce the risk of an undershoot. When 
starting below the target trajectory, a faster exponential normalisation of glucose 
values is specified reflecting the need to recover faster from low glucose values. 
For safety the control systems must be able to cope with exceptional 
circumstances. Four safety schemes protect against system failures and 
minimize the risk of insulin overdosing and subsequent hypoglycaemia. 
Safety scheme 1 monitors the relationship between a "normal" 
(model-independent) basal insulin rate, determined from total daily insulin dose, 
and a "model" basal rate determined by the MPC. Basal rate corresponds to the 
insulin infusion rate, which maintains glucose concentration at normoglycaemia. 
When model-based basal rate becomes substantially higher than the model-
independent basal rate, the MPC-derived infusion rate is deemed to be too high 
due to the system failure and is overridden by the model-independent basal rate. 
This signals that "estimated" subject's insulin resistance is transiently increased 
above a plausible threshold. The model-independent basal rate is used rather 
than a minimal dose (alternating 0.0 and 0.1 U/h to avoid pump occlusion) to 
provide an insulin supply comparable to that delivered without the use of the 
closed-loop control. 
Further safety schemes limit the insulin infusion to a minimum dose of 0.1 U/h 
when glucose is declining too fast (safety scheme 2), when glucose is below a 
specific threshold (safety scheme 3), or when glucose is administered 
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intravenously within the last 30min (safety scheme 4; designed for clinical tests 
only). 
3.4.5 Conclusion 
In conclusion, modelling of glucoregulation processes have fulfilled several of its 
purposes by allowing better understanding, increased knowledge, and facilitated 
patient management and education. Modelling was intensively employed to 
achieve an artificial pancreas (AP) but a comprehensive simulation environment 
for adequate testing of the AP is not available. Having in this chapter reviewed 
the various modelling approaches to the glucose metabolism in men, the next 
chapter is presenting a Type 1 diabetic model within a closed loop system 
employing CSII and subcutaneous glucose measurements. 
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4 Simulating Carbohydrate Metabolism in Type 1 
Diabetes 
4. 1 Introduction 
This chapter describes a model to simulate glucose excursions during fasting 
and fed conditions in Type 1 diabetes. The purpose is to have a sufficiently rich 
but not too complicated structure to facilitate the creation of an in silica 
population of subjects with Type 1 diabetes with a wide spectrum of behaviour. 
Such a population is described in the next chapter. 
The simulated subjects are designed to be used in the development of an 
extracorporeal pancreas. Therefore the simulated subjects must represent the 
input-output relationship anticipated with the artificial pancreas. In particular, this 
includes sensing of the subcutaneous glucose and the subcutaneous delivery of 
fast acting insulin. The model should also include physiological variables such as 
plasma glucose and plasma insulin for monitoring purposes. 
4.2 General Overview 
The model of subjects with Type 1 diabetes consists of a glucose kinetics 
subsystem (glucose absorption, distribution, and disposal), an insulin kinetics 
subsystem (insulin absorption, distribution, disposal), and an insulin action 
subsystem (insulin action on glucose transport, disposal, and endogenous 
production). As the model represents subject with Type 1 diabetes, a model of 
endogenous insulin secretion is omitted. 
The core of the model contains a published description of glucose kinetics and 
insulin action (42) building on recent experimental and modelling work, which 
employed glucose tracers to determine structure and parameter values of 
glucose kinetics in normal subjects during basal conditions and during the 
intravenous glucose tolerance test. 
The overall model structure is represented in Figure 4.1. 
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Figure 4. 1: Model structure of a simulated subject with Type 1 diabetes. 
4.3 Glucose Kinetics Subsystem 
At the heart of the model is a two-compartment representation of glucose 
kinetics described as 
(4.1 ) 
(4.2) 
(4.3) 
where 01 (mmol kg-1) and 02 (mmol kg-1) represent the masses of glucose in the 
accessible (where measurements are made) and non-accessible compartments, 
k12 (min-1) represents the transfer rate constant from the non-accessible to the 
accessible compartment, VG (I kg-1) represents the distribution volume of the 
accessible compartment, G (mmol r1) is the (measurable) glucose concentration, 
EGPo (IJmol kg-1 min-1) represents endogenous glucose production (EGP) 
extrapolated to the zero insulin concentration. UG(t) (mmol kg-1 min-1) represents 
gut absorption and ｆｯｾ＠ (IJmol kg-1 min-1) is the total non-insulin dependent 
glucose flux corrected for the ambient glucose concentration where 
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F01 
F.Oc1 = C G 
'01 
4.5 
if G > 4.5mmol 1-1 
otherwise 
(4.4) 
FR (mmol kg-1 min-1) is the renal glucose clearance above the glucose threshold 
GRT (mmol r1) 
if G > GRT 
otherwise 
where kRT (min-1) is the renal clearance rate. 
(4.5) 
The variables X1, X2, and X3 relate to the model of insulin action and are described 
in section 4.4. 
The glucose kinetics subsystem, together with the insulin action subsystem is 
shown in Figure 4.2. 
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Figure 4.2: Compartmental model of glucose kinetics and insulin action. 01 and 
02 represent masses in accessible (plasma) and non-accessible compartments, 
I represents plasma insulin, X1, X2, and X3 represent insulin action on glucose 
transport, disposal, and endogenous glucose production, for more details, see 
section 4.3 and 4.4. 
An example of model performance over one and a half days is shown in Figure 
4.3, which includes plots of plasma glucose, renal clearance, endogenous 
glucose production (EGP), non-insulin dependent glucose flux ＨｆｯｾＩＧ＠ insulin 
dependent glucose disposal (Fo2 )' and fluxes between the two compartments 
ＨｾＲ＠ and F21 )· 
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Figure 4.3: Sample simulation with the glucose kinetics subsystem over one and 
a half day. See text for details. 
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The simulation in Figure 4.3 shows good glucose control during fasting but, in 
the post meal states (meals given at 840min, 1140min, and 1500min with 40, 70 
and 60g carbohydrates (CHO), respectively), the plasma glucose concentration 
is high resulting in renal clearance of glucose. 
The simulation shown in Figure 4.3 employed parameters obtained from clinical 
experiments performed in 18 Type 1 subjects and generated from informed 
probability distributions. Further details about parameter estimation and 
generation are provided in Chapter 5 section 5.5.2. Figure 4.3 employs 
parameters of subject 8. 
The additional inputs to carry out the simulation include the provision of insulin 
action, see section 4.4, and the rate of gut absorption, see section 4.6. 
Parameter values of subject 8 were employed. 
Table 4.1: Parameters of the glucose kinetics subsystem (subject 8) used to 
generate the simulation presented in Figure 4.3. 
Foft: EGPo§ 
(IJmol kg-1 min-1) (IJmol kg-1 min-1) 
11.04 14.07 
+ Non-insulin dependent glucose flux 
k1211 
(10-2 x min-1) 
2.93 0.18 7.8 
§ Endogenous glucose production extrapolated to zero insulin concentration 
II Transfer rate from non-accessible to accessible compartment 
11 Volume of distribution of the accessible glucose compartment 
# Renal clearance threshold 
t Renal clearance rate 
4.4 Insulin Action Subsystem 
0.011 
The insulin action subsystem represents three actions of insulin on glucose 
kinetics (42) described as 
(4.6) 
(4.7) 
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(0.8) 
where I is the plasma insulin concentration (mU r1), X1 (min-1) , X2 (min-1), and X3 
(unitless) represent the (remote) effect of insulin on glucose 
distribution/transport, glucose disposal, and endogenous glucose production; kbi 
(min-1), i = 1 .. 3, represent deactivation rate constants, and kail i = 1 .. 3, represent 
activation rate constants. 
The three insulin sensitivities, SIT, SID and SIE" given in Table 4.2 represent the 
activities of insulin on the three glucose pathways. They are defined as the ratios 
of the activation and deactivation constants, i.e. SIT = ka1/kb1, SID = ka2/kb2, and 
SIE = ka3/kb3. I n combination with the activation constants, the insulin sensitivities 
provide an alternative and presumably more robust parameterisation than that 
obtained with the activation and deactivation constants. Furthermore, the use of 
insulin sensitivities facilitates a more natural and transparent description and 
comparison of the insulin action system. 
An example simulation with the insulin action subsystem is shown in Figure 4.4. 
The driving function, plasma insulin, is taken from section 4.5 (Figure 4.6). The 
model parameters used to carry out the simulation are given in Table 4.2. 
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Figure 4.4: Sample simulation with the insulin action subsystem over one and a 
half day. See text for details. 
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Table 4.2: Parameters of the insulin action subsystem (subject 8) used to 
generate simulation presented in Figure 4.4 
SIT* SID* SIE* kb1t kb2t kb3t 
(10-4 X min-1 per mU r1) (10-4 X per mU r1) (10-2 X min-1) 
30.0 1.70 219 0.32 21.95 3.23 
* S'T=ka1lkb11 SID = ka 21'kb 2 I S'E=ka/kb3 used as an alternative parameterisation 
t Deactivation rate parameters 
Figure 4.4 shows the activation and the deactivation of the insulin action 
compartments. In particular, it shows that the dynamics of the insulin action on 
glucose transport are slower compared to those associated with the other two 
insulin actions. 
4.5 Insulin Kinetics Subsystem 
The model represents the kinetics of subcutaneously delivered fast acting insulin 
such as Lispro. The model is shown in Figure 4.5. 
O(t) 
Insulin depot Delay compartment 
Figure 4.5: Subcutaneous insulin absorption model, see text for details. 
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The insulin kinetics subsystem is described as 
dS1(t) = U(t) _ S1(t) 
dt tmax,/ 
(4.9) 
dS2(t) _ S1(t) 
-
S2(t) (4.10) dt tmax,/ tmax,/ 
dl(t) S2(t) 
- ke/(t) (4.11) -dt v,tmax,/ 
where S1 (mU) and S2 (mU) is a two-compartment chain representing absorption 
of subcutaneously administered fast-acting insulin, U(t) represents administration 
(mU min-1) of insulin given as a series of micro boluses every three minutes 
and/or as big boluses at meal time. The constant tmax,' (min) corresponds to the 
time-to-maximum insulin absorption following an administration of a single bolus. 
I(t) (mU r1) is the plasma insulin concentration, ke (min-1) is the fractional 
elimination rate, and V, (I kg-1) is the distribution volume of insulin. 
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Figure 4.6: Insulin infusion rates (piecewise constant function), insulin bolus 
(vertical bars at 60, 840, 1140, and 1500) and the resulting plasma insulin 
profile. 
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An example of plasma insulin concentration resulting from insulin infusion and 
boluses over one and a half day is presented in Figure 4.6. The simulation 
employed parameters given in Table 4.3. 
Table 4.3. Parameter values for the insulin kinetics subsystem (subject 8) 
employed to generate the simulation shown in Figure 4.6. 
tmax,1 
(min)* 
35 12.0 
VI 
(10-2 xl kg-1)+ 
12.8 
* Time-to-maximum of absorption of subcutaneously injected fast acting insulin 
t Insulin elimination from plasma 
:1: Insulin distribution volume 
4.6 Gut Absorption Subsystem 
Glucose absorption entering the accessible glucose compartment is a 
fundamental process affecting postprandial glucose excursions. The subsystem 
is shown in Figure 4.7. 
CHO(t) 
1/tmax,G 1/t'max,G 
to plasma 
Figure 4.7: Glucose absorption subsystem 
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The model is described as 
d03 = _ 0 3 +CHO(t)8 
dt tmax.G 
(4.12) 
(4.13) 
(4.14 ) 
where Q3 (mmol) and Q4 (mmol) is a two-compartment chain representing 
absorption of carbohydrates from meals, CHO(t) (mmol) represents meal 
ingestion, 8(0/0) IS carbohydrate bioavailability, tmax.G (min) IS the 
time-of-maximum of the appearance of glucose in the accessible glucose 
compartment, and t'max,G is defined such as to limit the glucose appearance rate 
to a maximum of 0.025 mmol kg-1 min-1. 
ｴｾ｡ｸＮｇ＠ 0.025 
0 4 
if 04 < 0.025 mmol kg-1 min-1 
tmax.G 
otherwise 
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Figure 4.8: Sample simulation with the gut absorption subsystem with meals of 
40, 40, 70, and 60g CHO digested at 60, 840, 1140, and 1500min, respectively. 
A sample simulation using parameters given in Table 4.4 is shown in Figure 4.8 
demonstrating the absorption profiles of four meals of various sizes. The 
attainment of the limit in the absorption rate of 0.025 mmol kg-1 min-1 is not well 
marked but can be observed in the last two meals. 
Table 4.4: Parameters of the gut absorption subsystem (subject 8) used to 
generate Figure 4.8. 
*CHO bioavailability 
tmax,Gt 
(min) 
42 
tTime-to-maximum of CHO absorption subject to 25% variation 
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4.7 Interstitial Glucose Kinetics Subsystem 
The subcutaneous glucose kinetics subsystem is presented in Figure 4.9. 
-- ... -.... -... -- .... ＭＮＭＮＭＭＭＭＮｾ＠
Plasma glucose 
· 
· 
· 
· 
· 
· 
· 
· : kl21 
Interstitial glucose 
Figure 4.9: Interstitial glucose kinetics subsystem. 
The model equation is given as 
(4.16) 
where G and G, (mmol r1) represent plasma glucose and interstitial glucose 
concentrations, respectively ｫｾＲＧ＠ ｫｾＱＧ＠ and ｫｾＲ＠ (min-1) are transfer rate constants, 
ｫｾＲ＠ ］ｫｾＲ＠ ＫｫｾＲ＠ (min-1) IS an aggregated constant, I is the plasma insulin 
concentration (mU r1), S'I , IS insulin sensitivity associated with 
plasma-to-interstitial-fluid transfer (min-1 per mmol L-1), and ｆｾＲ＠ (10-2 mmol r1 
min-1) is the zero order glucose disposal. A sample simulation with the interstitial 
glucose kinetics subsystem is given in Figure 4.10. The simulation uses plasma 
glucose from an example in section 4.3 and plasma insulin from an example in 
section 4.5 as the forcing functions. The simulation example employs 
parameters given in Table 4.5. 
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Figure 4. 10: Sample simulation with the interstitial glucose kinetics subsystem. 
Table 4.5: Parameters of the interstitial glucose kinetics subsystem (subject 8) 
used to generate simulation in Figure 4.10 
KII * kl t 02 21 F102+ s:§ 
(10-2 x min-1) (10-2 X mmol r1 min-1) (10-4 X min-1 per mU r1) 
44.95 21.13 3.02 3.52 
* Transfer rate between the interstitial and plasma glucose compartment 
tTransfer rate between plasma glucose and interstitial glucose compartment 
+ Zero-order glucose disposal 
§ Insulin sensitivity of glucose transfer from the plasma to interstitial compartment 
4.8 Simulation Example 
This section combines all the subsystems to exemplify the input-output 
relationship. 
Figure 4. 11 shows a simulation example containing some of the variables 
presented in earlier sections. The plot shows the forcing function for the model, 
the insulin input (insulin infusion and insulin boluses), the other forcing function 
represented by meal intake, and the resulting profiles of plasma glucose and 
interstitial glucose. 
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Figure 4. 11: Simulation example over one and a half day. See text for details. 
The simulation covers approximately one and a half days. It represents an 
evening meal (60min), and an overnight fasting period followed by three meals at 
840min (breakfast), 1140min (lunch), and 1500min (dinner). The solid line is 
plasma glucose and the long dashed line represents interstitial glucose. The 
basal insulin delivery is represented by the piecewise constant function while 
boluses given at meal times are represented by vertical bars. The insulin profile 
is represented by the dash-double-dot line. 
4.9 Implementation 
The model is implemented in Matlab and its extension Simulink (The MathWork, 
I nc, Mass, USA). Matlab is a well-known package used to develop models and to 
perform system simulations. In association with Simulink, it is an ideal 
environment to facilitate symbolic system specification, visualisation, and 
programming. 
The Simulink block diagrams of the model and subsystems are presented In 
Appendix B 
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4.10 Discussion 
The purpose of this chapter was to present the overall model of a subject with 
Type 1 diabetes. A model 0 f insulin secretion was excluded. The idea was to 
create a model which is simple enough to represent the physiology while 
retaining richness to represent various types of patients and settings. The model 
contains five interlinked submodels. 
The glucose kinetics and insulin action submodels have been developed 
resorting to a tracer study and the classical methodology of model development 
(186). T he novelty of the submodels is in the partitioning of insulin action on 
distribution/transport, disposal, and endogenous production. However, the model 
was developed employing data collected in healthy subjects during fasting and 
the intravenous glucose tolerance test (IVGTT). In addition to absent insulin 
secretion, subject with Type 1 diabetes differ from healthy subjects, for example 
by presenting a deficient suppression of the endogenous glucose production 
(187). However, by adjusting model parameters, differences can be represented. 
The insulin absorption subsystem represents absorption of subcutaneous 
infused fast-acting insulin. Two absorption kinetics studies (57) provided the 
background for our two compartment chain model. The simulation results 
showed that the model adequately mimicked the absorption characteristics of the 
fast acting insulin. 
A model of subcutaneous glucose kinetics is essential for the development of a 
subcutaneous-subcutaneous glucose controller. The transfer of glucose from 
plasma to the interstitial fluid introduces delays and a variable ratio between 
intravenous and interstitial glucose has been reported. This outlines the 
difficulties when using interstitial glucose for monitoring plasma glucose. 
Alongside this work, a modelling study was performed as part of another PhD 
thesis (188). Among several model structures, the best model, i.e. the model 
which best represented the experimental data, was selected by comparing the 
model fit error and by using the principle of parsimony as implemented by the 
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Akaike criterion (186). The measurement process employing interstitial glucose 
is described in details in the next chapter. 
Gut absorption is a complex process which has been studied extensively. 
However, to our knowledge, no viable complex model is available and results are 
inconsistent. It follows that employing a very complex model was not justified. 
We therefore resorted to a structure using a two compartment chain. Tracer 
studies (187,189,190) evaluated the rate of absorption and our simulations are 
consistent with the experimental data. The studies included the oral glucose 
tolerance test (189,190) and the ingestion of mixed meals (187,191). 
4.11 Conclusion 
This chapter has presented a model of carbohydrate metabolism in subjects with 
Type 1 diabetes. Several subsystems have been combined in a modular way to 
simulate plasma and interstitial glucose kinetics based on subcutaneous delivery 
of fast acting insulin and the digestion of meals. 
Supplied with appropriate parameters, the model has the potential to simulate a 
range of subjects. The generation of virtual subjects is described in the following 
chapter. 
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5 Simulation Environment 
5. 1 Introduction 
In Chapter 4 a model of fundamental glucoregulatory processes in a subject with 
Type 1 diabetes was presented. The model includes submodels corresponding to 
physiological subsystems. Each submodel is defined by its structure and its 
behaviour is determined by associated parameter values. 
An important aspect in testing glucose controllers is an evaluation of their 
performance in a range of subjects and not just in an "average" representative of a 
population with Type 1 diabetes. The controller has to be able to cope with a variety 
of behaviour ranging from insulin sensitive to insulin insensitive subjects, a delayed 
absorption of insulin, a faster absorption of carbohydrates following meal ingestion 
etc. This can be achieved by creating a virtual population of subjects. This 
representation of inter-subject variability should also be complemented by 
representing intra-subject variability, i.e. representing changes in metabolic settings 
during a day. 
The present chapter describes the generation of a virtual population consisting of 18 
subjects with Type 1 diabetes. This is achieved by assigning different parameter 
values to the common model structure. The chapter also includes the description of 
two additional submodels, a model of a glucose sensor and a model of an insulin 
pump, which together facilitate the establishment of the simulator, a complete 
environment for in silica testing of glucose controllers. 
5.2 General Overview of Simulation Environment 
The overall layout of the simulator environment is shown in Figure 5. 1. It includes 
two main blocks, the simulator and the controller block. In the thesis, the control 
action is every 15 minutes. Therefore the simulator block will send historical data 
needed by the MPC controller every 15 minutes allowing the generation of a new 
insulin infusion rate. 
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The simulator includes the virtual subject represented by a physiologically-based 
compartmental glucoregulatory model described by a set of first order differential 
equations based on work by Hovorka et al (42) and presented in greater detail in 
Chapter 4. The measurement model block represents the measurement process and 
includes the properties of the glucose sensor such as the measurement error. The 
insulin pump delivers the insulin into the sUbcutaneous tissue of the virtual subject 
and can also be parameterised to include an error in the insulin delivery due to 
technical limitations and tissue properties. The simulation environment is 
implemented in Matlab and Simulink®. 
The glucose controller is "outside" the environment in the sense that it is a separate 
computer program, which is started from within the Matlab code. The data exchange 
between the Matlab code and the controller is via ASCII files. This facilitates the 
testing of various controllers, which implement a specific format for the data 
exchange. 
Simulator 
Meal 
Simulated Human , . . . . . . 
• • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • 
· \ 
It 
• 
• Glucose 
"-
• Absorption Model " Glucose • 
• Kinetic S.C. Glucose • ｾｾ＠• &Insulin Action Kinetics 
• I nsulin Kinetic Model • Insulin Absorption ｾ＠ ｾ＠• Model Model 
• i. v. s.c. 
• 
• If', • · ...... • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • 
s.c. insulin \lJ' \lJ' 
I nsuli n Pump Glucose 
Model Sensi ng Model 
)f', 
Controller 
Control action Measurement 
every 15 min Control every 15 min 
Algorithm ........ 
Figure 5.1: An overall layout of the simulation environment which include a ｳｩｭｵｬ｡ｴｾ､＠
subject with Type 1 diabetes within the closed-loop control framework with 
measurement and insulin pump models and control algonthm to close the loop. 
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5.3 Insulin Pump Model 
Discrepancies occur between the pump commands and the amount of insulin 
actually delivered. Figure 5.2 presents the approach employed to represent the 
inclusion of errors in the delivery of insulin due to mechanical imprecision associated 
with the Disetronic D-Tron pump, which was used in clinical trials. Following the 
technical description of the pump, the simulated insulin delivery was represented by 
mini boluses three minutes apart. 
The inaccuracies in the insulin infusion rate were represented by a normally 
distributed error with a zero mean and a coefficient of variation of 15%. The bolus 
was excluded from this process a s flow rates are higher and the delivery error is 
likely to be negligible. 
Insulin delivery command 
Insulin infusion 
rate 
I 
Insulin bolus 
Noise I ｾ｟ｃ｟ｖ｟］｟ＱＵ｟ｾ｟ｯ＠ __ ｾＭＭＭＭＭＭＭＭＭｾＧｾＱ＠
Delivered insulin 
(microbolus every 3 minutes) 
U(t) 
Figure 5.2: Model of insulin pump. U(t) represents insulin actually delivered by the 
pump. The noise is only associated with the insulin infusion rate because of the very 
small flow rates involved. 
Figure 5.3 shows the actually delivered insulin infusion rate delivered in the form of 
microboluses at a 3 minutes interval. The intended, commanded insulin infusion rate 
is also shown. 
55 
Chapter 5: Simulation Environment 
140 
-- Insulin rate pump command 
120 Insulin rate delivered 
-
., 
100 :. c ｾ＠
E ; '. 
" 
-
\ 
" :::> ' , \ " ,. I , ｾ＠, E 80 "' . , ｾＺ＠ t , ｾ＠
--
\ ｾ＠
• ｾ＠If) ;,. 
ID .' ｾ＠
-
.. . ;. ' . ｾ＠ , ｾ＠ " '. 60 , " r·. ｾ＠:-c t . . '. • · . . '. .. , ｾ＠ ｾ＠ ｾ＠ ｾ＠ . ::J . ., ,. · . .. · . t: ｾ＠ n ｾ＠If) . ' · . . · . c 40 ...! · . • ｾＮ＠ 'V · . ｦｾ＠ ｾ＠ Ｚｾ＠ ｾ＠ｾ＠ .. · . ... 
f' "'V .. .. .. 
20 
:f. ＺﾷＮＺＮｾｴｾｬｲ＠' .. 
. :. 
0 
0 500 1000 1500 2000 
Time (min) 
Figure 5.3: The commanded and the actually delivered insulin during a simulated trial 
with a model predictive controller. The actual infusion rate was delivered in the form 
of microboluses 3 min apart and a delivery error with a 15% CV. 
5.4 Glucose Measurement Model 
Within the framework of a minimally invasive artificial pancreas, the measurement of 
glucose employs subcutaneous sensing. Subcutaneous glucose measurements 
require calibration as there exist individual differences between plasma and 
interstitial glucose concentrations. Sensing is also corrupted by measurement error. 
Figure 5.4 depicts the steps associated with determining the glucose measurement 
from the interstitial glucose concentration. These two processes, the calibration and 
the measurement error, were implemented in the simulator. 
5.4.1 Calibration Model 
Ideally, the subcutaneous glucose model presented in Chapter 4, section 4.7, could 
be employed to simulate the calibration procedure. However, the model relies on the 
knowledge of t he plasma insulin concentration which is not available in real time. 
Therefore, to reproduce the experimental conditions, a simpler subcutaneous 
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glucose model which is not dependent on insulin level was employed, see Figure 
5.5. 
The former model was shown to be only marginally better in explaining experimental 
data (188) than its insulin free counterpart. Although, the model used for the 
calibration did not include the insulin effect on the glucose transfer from the plasma 
to the subcutaneous compartment, the data showed that IG/PG ratio increased by 
only 0.03 per 10mU/L. The consequence of removing the insulin effect from the 
simulations is therefore small. 
Due to the lack of knowledge of individual subcutaneous model parameters, 
population parameter estimates were used as calibration constants (135,188,192). 
SC glucose 
Calibration 
..... 
parameter kl21 ｾ＠
v 
Calibrated 
glucose 
Measurement 
..... 
ｾ＠
error 
" Glucose 
measurement 
Figure 5.4: The sequence of determining glucose measurement from the 
subcutaneous glucose concentration. 
The calibration consists of determining the parameter ｫｾＱ＠ from the simulated plasma 
glucose and interstitial glucose measurements. 
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In particular, simulated plasma glucose Go is taken at time to' A patient specific 
parameter ｫｾＱ＠ is then derived from the steady state solution of equation (5.3) where: 
(5.1 ) 
where G, is the simulated interstitial glucose concentration obtained from the 
interstitial glucose subsystem presented in section 4.7, ｫｾＲｐ＠ is the transfer rate from 
the interstitial glucose to plasma glucose compartment, Fd2P is the zero order 
disposal from the interstitial glucose compartment. Population values of parameters 
ｫｾＲｐ＠ and Fd2P are used in these calculations, ｫｾＲｐ＠ =0.04 76min-1 and Fd2P = 0.0404 
mM-1 min-1 (135,188). 
Plasma glucose is then calculated from interstitial glucose uSing the individually 
determined value of ｫｾＱ＠ as 
(5.2) 
Plasma Glucose Interstitial Glucose 
Figure 5.5: Model of subcutaneous glucose kinetics used for the calibration. 
The model of the subcutaneous glucose kinetics employed for the calibration IS 
shown in Figure 5.5. The model is represented byequation (5.3) 
dG, 'G k' G F' 
- = k21 - 12P I - 02P 
dt 
(5.3) 
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5.4.2 Measurement Error 
A measurement error can be set to a specific value reflecting the performance of the 
measurement device. Throughout the investigations, a normally distributed 
measurement error was employed with a zero mean and a constant coefficient of 
variation. Unless stated otherwise, the CV was set at a level of 5%. 
5.5 Inter-Subject Variability 
5.5.1 Introduction 
A characteristic of human physiology is the presence of differences between and 
within subjects. The aim of this section is two fold. First to present the approach 
employed by the simulator to account for inter-subject variability and, secondly, the 
method employed to introduce intra-subject variability. 
18 synthetic subjects have been generated employing clinical data and probability 
distributions. The number of subjects was dictated by the availability of clinical data 
to determine the core of the model, i.e. the submodel of glucose kinetics and insulin 
action. 
5.5.2 Glucose Kinetics Subsystem 
The glucose kinetics subsystem was described in section 4.3, Chapter 4. It has six 
parameters. In conjunction with the model of insulin action it establishes the core of 
the model. 
The determination of model parameters for an individual synthetic subject followed a 
two stage process. In the first stage, a subset of parameters was estimated from 
experimental data while other parameters were fixed at expected population values. 
In the second stage, the previously fixed parameters were sampled from univariate 
informed distributions. 
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Data for the first stage came from a clinical trial carried out in 18 subjects with Type 1 
diabetes (data not shown). The experiment involved intravenous insulin infusion to 
maintain euglycaemia and lasted from 2200 until 0700 the following morning. Plasma 
glucose was sampled every 10 minutes and plasma insulin was sampled every 30 
minutes. 
The glucose kinetics and the insulin action submodels represent the relationship 
present in the experiment. Plasma insulin is the input and plasma glucose is the 
output. The experiment excluded subcutaneous insulin delivery and gut absorption. 
Due to identifiability issues (186) it was not however possible to estimate all 12 
parameters of the two submodels. Therefore, parameters which were deemed not a 
posteriori identifiable from the experimental data were fixed at population values as 
obtained in Hovorka eta I (42). T his I eft five parameters to bee stimated from the 
experimental data: the non insulin dependent glucose flux F01 ' endogenous glucose 
production extrapolated to the zero insulin concentration EGPo ' and the three insulin 
These five parameters were successfully estimated f rom the data using Bayesian 
parameter estimation implemented in SAAM " (SAAM Institute, Seattle, USA). The 
resulting values are shown in Table 5.1 and Table 5.2. 
The second stage involved the generation of parameters values fixed during the first 
stage. The process was carried out to expand the inter-subject variability obtained 
during the first stage. 
The generated parameter values are also shown in Table 5.1 and Table 5.2 . The 
tables include information about the generating distributions, its values, bracketing 
information, and where possible the literature source justifying the choice. 
Regarding the choice of the generating distributions, the log-normal distribution was 
used for all parameters except the renal clearance threshold tor epresent skewed 
distribution and to guarantee non-negativity. 
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Table 5.1: Parameters of the glucose kinetics subsystem for the 18 synthetic 
subjects. 
Subject 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
1 1 
12 
13 
14 
15 
16 
17 
18 
F01+ EGPo§ 
(I-lmol kg-1 min-1) 
11.01 19.62 
8.31 9.10 
4.40 6.42 
6.88 8.25 
5.09 
8.74 
5.25 
11.04 
6.61 
3.37 
10.19 
2.37 
12.03 
10.08 
4.09 
5.00 
8.23 
4.01 
11.92 
10.49 
17.09 
14.07 
7.16 
4.35 
12.19 
17.54 
13.89 
11.81 
12.26 
7.09 
14.74 
11.94 
k1211 ｖｇｾ＠
(10-2 x min-1) (10-2 x I kg-1) 
10.95 17.9 
5.09 14.5 
7.67 17.4 
6.35 17.8 
2.90 
3.07 
5.46 
2.93 
6.72 
5.37 
6.70 
9.06 
5.09 
5.78 
7.39 
3.20 
3.07 
4.79 
12.5 
14.6 
16.8 
18.0 
9.3 
13.2 
14.2 
14.0 
16.4 
10.6 
11.9 
14.7 
16.5 
16.5 
+ Non-insulin dependent glucose flux; derived from clinical data 
11.7 
9.2 
8.1 
10.1 
12.4 
7.7 
9.3 
7.8 
8.2 
7.5 
10.3 
11.6 
8.6 
8.2 
8.5 
13.0 
10.3 
11.3 
0.012 
0.013 
0.006 
0.011 
0.012 
0.010 
0.006 
0.011 
0.007 
0.011 
0.013 
0.013 
0.011 
0.008 
0.012 
0.012 
0.007 
0.007 
§ Endogenous glucose production extrapolated to zero insulin concentration; derived from 
clinical data 
II Transfer rate constant from the non-accessible to accessible compartment; log 
transformed parameter was drawn from N( -2.813, 0.432) bracketed by [0.01-0.2] (42) 
ｾ＠ The glucose volume of distribution; log transformed parameter was drawn from N(-1.897, 
0.232) bracketed by [0.09-0.25] (42) 
# The renal clearance threshold; drawn from N(9, 1.52) bracketed by [7.5-15.0] 
t The renal clearance rate N(0.01 ,0.0252) bracketed by [0.003-0.03] 
5.5.3 Insulin Action Subsystem Parameters 
Table 5.2 shows parameters of the insulin action subsystem. With the provision of 
the plasma insulin concentration they quantify insulin action on the glucose kinetics 
as presented in Chapter 4 section 4.4. Insulin sensitivities S'T' S'D' and S'E were 
generated from experimental data, the deactivation rate constants were generated 
employing random selection from log normal distributions. 
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Table 5.2: Parameters of the insulin action submodel 
Subject SIT* SIO* SIE* kb1t kb2tt kb3# (10-4 X min-1 per mU r1) (10-4 x mU r1) (10-2 X min-1) 
1 77.1 3.14 377 0.21 39.56 8.03 
2 11.0 1.58 73 0.06 1.36 2.02 
3 8.5 12.32 71 0.34 5.34 2.09 
4 11.9 6.64 116 0.14 13.77 2.10 
5 11.6 7.39 222 0.80 9.19 4.26 
6 12.4 1.53 114 0.07 3.69 3.39 
7 7.7 3.13 404 0.11 6.07 4.52 
8 30.0 1.70 219 0.32 21.95 3.23 
9 8.6 3.84 75 0.46 2.85 5.02 
10 5.4 12.00 53 0.48 4.42 1.66 
11 23.5 1.84 129 0.14 15.92 2.22 
12 7.4 2.37 472 0.40 5.76 3.39 
13 35.2 1.26 163 0.10 8.05 1.59 
14 18.3 1.56 161 0.26 11.56 2.76 
15 12.4 16.52 346 0.14 3.73 8.53 
16 9.9 17.60 137 1.11 1.19 4.24 
17 27.9 3.94 197 0.25 7.84 1.52 
18 12.6 11.31 169 0.51 4.17 5.49 
*S'T = ka/kb1' SID = ka Ikb 2 , S'E = ka:lkb3 used as an alternative parameterisation; for more 
information see text; derived from clinical data 
t Log transformed deactivation rate parameter was drawn from N(-5.684, 1.002) bracketed 
by [0.0002-0.0500] (42). 
tt Log transformed deactivation rate parameter was drawn from N(-2.882, 0.752) 
bracketed by [0.0050-0.4000] (42). 
# Log transformed deactivation rate parameter was drawn from N( -3.730, 0.752) bracketed 
by [0.0030-0.1000] (42). 
5.5.4 Insulin Kinetics Subsystem 
The insulin kinetics subsystem has three parameters which determine the plasma 
insulin concentration profile from the subcutaneous insulin delivery by the pump. The 
parameters of the insulin absorption subsystem are presented in Table 5.3. The 
generation of the parameters involved a random selection from informed univariate 
normal distributions. 
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Table 5.3: Parameter of the insulin absorption submodel 
1 50 13.2 11.3 
2 63 10.1 13.1 
3 70 15.2 12.2 
4 40 14.0 13.0 
5 58 11.5 12.8 
6 39 17.7 11.5 
7 40 14.4 12.3 
8 35 12.0 12.8 
9 93 17.4 9.8 
10 41 16.7 12.9 
11 42 26.3 12.4 
12 42 11.2 12.7 
13 41 16.6 11.4 
14 49 15.6 12.2 
15 50 15.9 11.1 
16 29 10.5 8.6 
17 36 12.5 12.4 
18 45 12.8 13.0 
*Time-to-maximum of absorption of subcutaneously injected fast acting insulin 
tmaxl=1/ka; where ka is drawn from N(0.01B, 0.00452) bracketed by [0.005 - 0.060] 
(46) 
t Insulin elimination from plasma; drawn from N(0.14, 0.03452) bracketed by 
[0.050 - 0.300] (42) 
t Insulin distribution volume; drawn from N(0.12, 0.0122) bracketed by [O.OBO -
0.1BO] (42) 
5.5.5 Gut Absorption Subsystem 
Meal responses are known to vary greatly between and within subjects. Meal 
composition, the time of day, and the nature of carbohydrates are some of the 
numerous factors that influence the meal effect on the plasma glucose concentration. 
The model of gut absorption includes two parameters, the bioavailability 8 and the 
time to peak of gut absorption tmax,G. The bioavailability comprises two types of 
information. First, it is the true physiological bioavailability of digested carbohydrates 
in a mixed meal. Second, it is the mis-specification of the actual carbohydrates 
(CHO) content in the meal. Due to the latter, the bioavailability can exceed 100% 
representing underestimation of CHO in the meal. 
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The two parameters of the gut absorption subsystem were generated employing 
random selection from a uniform distribution for the bioavailability and a log normal 
distribution for the absorption rate parameter, see Table 5.4. 
Table 5.4: Parameters of the glucose absorption model 
8* Subject (%) 
1 71 
2 90 
3 113 
4 77 
5 82 
6 72 
7 72 
8 78 
9 81 
10 71 
11 84 
12 87 
13 98 
14 88 
15 89 
16 88 
17 116 
18 79 
* CHO bioavailability; drawn from U(70; 120) 
tmax,Gt 
(min) 
43 
55 
38 
29 
30 
54 
69 
42 
30 
52 
48 
61 
63 
51 
49 
68 
46 
44 
tTime-to-maximum of CHO absorption, tmax,G=1 /a, where a is log transformed 
parameter drawn from N(-3.689, 0.252) bracketed by [0.010 - 0.040] (189) 
5.5.6 Interstitial Glucose Kinetics 
The model of the interstitial glucose kinetics includes four parameters. The 
parameters were generated using information about their distributions as described 
by Wilinska et al (135). In particular the parameters ｫｾＱ＠ and ｫｾＲ＠ were found strongly 
correlated. 
The parameters of the subcutaneous glucose kinetics are shown in Table 5.5. 
Parameters were drawn from a log normal distribution with the exception of ｫｾＱ＠
which was correlated with ｫｾＲＧ＠ The mean and the standard deviation of the ratio 
ｫｾＱ＠ / ｫｾＲ＠ were employed to generate a random ratio to derive ｫｾＱ＠ using a random 
draw of ｫｾＲＧ＠
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Table 5.5: Parameters of the model of subcutaneous glucose kinetics 
kl * kl21t I SII§ 
Subject 12 F 02+ (10-2 X min-1) (10-2 X mmor1 r1 min-1) (10-4 x min-1 per mU r1) 
1 16.12 10.55 3.37 0.70 
2 2.27 1.61 1.18 0.21 
3 25.25 20.06 6.05 5.36 
4 13.01 28.03 18.34 0.32 
5 8.68 12.12 16.86 1.49 
6 3.35 4.70 29.95 0.86 
7 17.00 15.13 0.45 0.25 
8 7.88 6.53 3.62 4.72 
9 2.33 3.89 4.97 6.84 
10 2.87 2.08 1.45 0.43 
1 1 3.16 2.73 2.22 1.05 
12 10.39 11.65 0.76 0.31 
13 28.68 16.56 0.64 3.33 
14 21.55 12.94 1.63 0.21 
15 5.58 2.24 2.03 2.21 
16 9.20 4.35 0.48 2.48 
17 17.12 9.90 2.53 0.88 
18 44.95 21.13 3.02 3.52 
*Transfer rate parameter between interstitial and plasma glucose compartment; 
log transformed parameter drawn from N(-2.372, 1.092) (135) 
tTransfer rate between the plasma glucose and interstitial glucose compartment; 
derived from k' 21= r*k'12' where r although not normally distributed was drawn 
from a normal distribution N(0.630, 0.152) bracketed by [-1.00 -1.00] (135) 
:1: Zero-order glucose disposal parameter; log transformed parameter drawn from 
N(-3.066, 1.072 ) (135) 
§ Insulin sensitivity of glucose transfer from the plasma to interstitial 
compartment; log transformed parameter drawn from N(-8.517, 1.452) (135) 
5.6 Intra-Subject Variability 
5.6.1 Introduction 
The inter-subject variability was introduced by assigning a unique set of parameters 
to each synthetic subject. In order to increase the realism a nd to represent more 
closely the physiology it is necessary to introduce the intra-subject variability 
representing diurnal variations and unmodelled effects. 
The intra-subject variability was introduced employing two methods. First, oscillations 
were superimposed upon parameters values, i.e. certain model parameters were 
made time-variant. Second, an inter-occasion variability in gut absorption was used 
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to represent the variability in the meal absorption due to the meal composition and 
other effects causing a lower reproducibility of postprandial glucose excursions 
(193,194). 
5.6.2 Parameter Variation 
The pnmary route to include the intra-subject variability involved introducing 
oscillations in model parameters. Sinusoidal oscillations were superimposed on 
nominal values of most parameters, see Table 5.6. The variability in gut absorption 
was represented in a different fashion, see section 5.6.3. 
The superimposed oscillations had a five percent amplitude and a three hour period. 
These characteristics were the same for all time variant parameters. However, each 
parameter had a different phase generated randomly from a uniform distribution 
U[O,3h]. 
Oscillatory parameters with different phases influence the unique behaviour of the 
synthetic subjects. The parameters can be in-phase or out-of-phase, increasing, for 
example, the oscillations in overall insulin sensitivity. 
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Table 5.6: Model parameters can be time-variant (oscillatory) or time-invariant 
(stationary). 
Parameter Variability 
tmax,1 Oscillatory* 
ke Oscillatory 
VI Stationary 
B Stationary 
tmax,G Stationaryt 
kb1 Oscillatory 
kb2 Oscillatory 
kb3 Oscillatory 
SIT Oscillatory 
SID Oscillatory 
SIE Oscillatory 
F01 Oscillatory 
EGPo Oscillatory 
k12 Oscillatory 
VG Stationary 
GRT Stationary 
KRT Stationary 
ｋｾＲ＠ Oscillatory 
ｋｾＱ＠ Oscillatory 
FI Oscillatory 02 
SI Oscillatory 
1 
*Sinusoidal oscillations; for details see text 
tSubject to an additional 25% variability at each meal intake 
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Figure 5.6: An example of parameter variation with the nominal value shown as a 
solid horizontal line and the varying profile as a dashed line. 
The amplitude of oscillation influences the ability of the glucose controller to achieve 
normoglycaemia. This is exemplified in Figure 5.7 and Figure 5.B. The former figure 
shows control with a 50/0 amplitude in parameter oscillations in subject 14, the latter 
figure shows control with a 30% amplitude. 
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Figure 5.7: A sample simulation of subject 14 with a 5% sinusoidal oscillation 
superimposed upon time-variant parameters. 
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Figure 5.8: A sample simulation of subject 14 with a 30% sinusoidal oscillation 
superimposed upon time-variant parameters except parameters of the subcutaneous 
glucose kinetics left at the 5% amplitude. 
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It is evident that glucose excursion in subject 14 becomes more oscillatory with a 
30% amplitude. 
5.6.3 Variability in Glucose Absorption Rate 
Due to a complex range of processes involved in meal digestion, similar meals or 
even the same meal can result in different gut absorption profiles (46). It is therefore 
important to include some variability in the absorption rate. 
In the simulator, the bioavailability is not subjected to an inter-occasion variability but 
the absorption rate is associated with a 25% inter-occasion variability. 
The effect of the inter-occasion variability is shown in Figure 5.9, which presents 
simulation runs with identical conditions up to the last meal at 1500min. The fixed 
absorption rate is then relaxed to include the 25% variability, normally included for all 
meals. 
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Figure 5.9: Simulations of the glucose absorption profile including a random variation 
in the absorption rate for the last meal (meals of 40, 40, 70, and 60g CHO at 60, 840, 
1140, and 1500min). 
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Figure 5. 10: Simulations with a glucose controller using the glucose absorption 
profiles of Figure 5. 9 as the forcing functions. 
The absorption rates profiles in Figure 5. 9 show the effect of the variation in the 
speed of absorption of two meals of 60g of CHO. Figure 5.10 shows the resulting 
glucose profiles with a higher peak followed by a minor undershoot with the faster 
gut absorption profile. 
5.7 Characteristics of Synthetic Subjects 
The generation process described in the previous section produced 18 distinct 
synthetic subjects. Table 5.7 summarises the subjects by weight, insulin needs, and 
controllability employing a model predictive controller described in section Chapter 3, 
section 3.4.4. Table 5.7 demonstrates a wide spectrum of insulin sensitivities 
represented by the group of synthetic subjects. The classification of controllability 
follows an assessment of control with regards to avoiding hypoglycaemia while 
achieving normoglycaemia and is based on an overall experience with the behaviour 
of the synthetic subjects under various conditions. The controllability ranges from 1 
(easy to control) to 5 (difficult to control) where the latter represent cases unlikely to 
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be seen in clinical practice. The number of cases in categories 1 to 5 was 2, 7, 6, 1 
and 2. 
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Table 5.7: Overall characteristics of 18 synthetic subjects 
Subject Weight Basal needs (kg) (mU/kg/h) 
1 69 7 
2 90 14 
3 62 15 
4 87 1 1 
5 75 9 
6 107 16 
Prandial needs 
(U/10g CHO) 
0.7 
2.3 
1.6 
1.6 
0.5 
3.4 
Comments 
Very insulin sensitive and 
prone to hypoglycaemia 
High postprandial 
glucose amplitude; 
insulin resistant; PG/IG 
lag 
High postmeal excursions 
Tendency to long lasting 
post meal excursions 
High glucose amplitude; 
very insulin sensitive 
Very insulin resistant; 
higher glucose values 
even during fasting 
*Rating 1 to 5; 1 represents an easy to control subject, 5 represents a difficult to control subject. 
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Subjective 
* controllability 
5 
4 
3 
2 
3 
3 
Table 5.8: Cant 
Subject Weight Basal needs (kg) (mU/kg/h) 
7 51 22 
8 76 9 
9 80 15 
10 101 13 
1 1 73 26 
12 60 25 
Prandial needs 
(U/10g CHO) 
1.4 
0.5 
1.9 
3.0 
3.1 
2.1 
Comments 
Oscillatory glucose 
excursions; marked 
postmeal excursions; 
insulin resistant 
Insulin sensitive; very 
easy to control 
Extremely large 
postprandial glucose 
excursions; insulin 
sensitive 
Post meal resistant 
Insulin resistant; relative 
moderation in the 
postmeal phase 
The most resistant subject 
Insulin resistant; 
tendency to stay in the 
above target glucose 
levels 
*Rating 1 to 5. 1 represents an easy to control subject, 5 represents a difficult to control subject. 
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Subjective 
* controllability 
3 
1 
5 
2 
2 
2 
Table 5.9: Cant 
Subject Weight Basal needs (kg) (mU/kg/h) 
13 75 12 
14 60 20 
15 63 13 
16 79 5 
17 72 1 1 
18 65 14 
Prandial needs 
(U/10g CHO) 
1.6 
1.6 
1.0 
0.5 
0.9 
0.8 
Comments 
Stable control; tendency 
to stay at the above target 
glucose levels 
Insulin resistant; 
prolonged postprandial 
glucose excursions 
Oscillatory glucose 
excursions; insulin 
sensitive; 
a large PG/IG mismatch 
Very insulin sensitive; 
good control 
Insulin sensitive 
particularly to insulin bolus 
Insulin sensitive; stable 
glucose control 
*Rating 1 to 5. 1 represents an easy to control subject, 5 represents a difficult to control subject. 
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2 
3 
3 
1 
2 
2 
Chapter 5: Simulation Environment 
The following three examples demonstrate differences among the subjects. 
Figure 5.11 shows simulation with subject 5, who is difficult to control. 
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Figure 5. 11: A sample simulation of a subject difficult to control (subject 5). 
See text for details of the experiment. 
The plot shows plasma glucose (solid smooth line), the interstitial glucose 
measurements sampled every three minutes (5% measurement error; solid 
ragged line), the insulin infusion rate (piecewise constant solid line) and 
insulin boluses (open bars) delivered by the controller, and the plasma insulin 
concentration (dash-dot line). During the MPC controlled period, the subject 
ingested three meals at 840, 1140 and 1500 of 40, 70 and 60g CHO 
respectively. The insulin infusion rate was generated by the MPC described in 
section 3.4.3. 
Subject 5 is characterised by large glucose fluctuations with steep glucose 
changes. The glucose profile presents both low and high glucose levels, the 
latter following meal digestion. The insulin sensitivity of the subject prevents 
large amount of insulin to be administrated to correct for glucose peaks. 
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Figure 5. 12: A sample simulation of a subject with high insulin requirements 
(subject 11). For details of the simulated experiment, see Figure 5. 11. 
Figure 5. 12 shows a simulation with subject 11 also presenting considerable 
fluctuations in glucose levels. However, the hypoglycaemic range is not 
approached. This subject is characterised by high insulin requirements. 
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Figure 5. 13: A sample simulation of a subject easy to control easy control 
case (subject 8). See Text for details of the experiment. 
Figure 5. 13 shows a simulation with subject 8 who, despite the presence of 
some oscillations, is easy to control. The glucose is never in the proximity of 
the hypoglycaemic threshold of 3.3mM. Elevated glucose levels either in the 
fasting or fed states are absent. 
Appendix A shows simulations with all 18 subjects. 
5.8 Discussion 
The model of the glucoreglatory system in subjects with Type 1 diabetes was 
discussed in Chapter 3. Utilising the model, the purpose of the present 
chapter is to describe a simulation environment, which would enable glucose 
controllers to be tested. 
To evaluate systematically a glucose controller, the simulation environment 
needs to represent a wide spectrum of subjects and include noise in the 
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insulin delivery and in glucose measurements. In our approach both 
inter-subject and intra-subjects variability were represented. 
The sensing unit needs to represent certain characteristics for successful use 
with a closed-loop control system. It has been the focus of research for 
decades. The availability of a reliable subcutaneous glucose sensor is often 
considered the main obstacle for the development of an extracorporeal 
artificial pancreas (AP). 
It is currently unclear what the real performance of a glucose sensor with a 
closed-loop system should be. A choice of a 50/0 measurement error presents 
an informed guess based on the data available with existing prototypes. 
Insulin pumps are very reliable and versatile. However insulin delivery is not 
error-free especially at very low rates. It was therefore necessary to represent 
these pump errors. The delivery error was set at the level of 15% following an 
assessment of technical information provided for the Disetronic D-Tron pump. 
The pump delivery error is not thought to pose a problem because of the 
relatively long time constant of the subcutaneous insulin absorption with a 
peak concentration at 71 ±17min (6) and 61 ±12min (195). 
From the random generation and clinically derived 18 sets of parameters 18 
synthetic subjects were obtained with Type 1 diabetes treated by continuous 
infusion of insulin lispro. 
The variation in the subcutaneous insulin absorption is likely to generate large 
inter- and intra-subject variability (196). The absorption is a complex process 
affected by factors such as catheter insertion, skin sickness, or the duration of 
catheter placement (197). 
Over and above oscillatory variations, other types of variations could have 
been included such as variation due to the dawn phenomenon. However, it is 
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unclear which parameters are affected. This could be insulin sensitivity (198) 
or hepatic glucose output (199). 
In addition to representing a major disturbance, the meal intake is introducing 
variability into the glucoregulatory system. As gut absorption is an extremely 
complex process, the experimental results are conflicting (200). Meal timing 
appears to influence insulin requirements (201). Studies with meals with high 
fat (34), high protein (202), or different types of carbohydrates have shown to 
affect the glucose response. Other factors like circadian rhythmicity are also 
known to introduce variability in the response to meals (203,204). 
Another aspect justifying the integration of variability in bioavailability is of a 
practical origin. The total carbohydrate content can be over- or 
under-estimated by the subject. A controller will have to use this information 
and should therefore demonstrate a certain level of insensitivity to those 
variations. 
5.9 Conclusion 
The parameter generation process resulted in a wide spectrum of subjects 
with large differences in fasting and prandial insulin requirements and with 
different levels of controllability. By combining a model of glucose 
measurements and a model of insulin delivery with a model of Type 1 
diabetes, a closed-loop system can be simulated to test insulin infusion 
strategies. 
The generation of 18 synthetic subjects facilitated the creation of a rich testing 
environment which will be employed in the development of a testing strategy 
presented in Chapter 6. 
The validation of the simulator is the central topic of Chapter 7, where clinical 
validity and limitations are assessed using a comparative study with real 
clinical data obtained in subjects treated by a model predictive controller. 
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6 Evaluation of Glucose Controllers in Virtual 
Environment: Methodology and Sample Application 
6. 1 Introduction 
As demonstrated in Chapter 2, glucoregulation is a complex process and 
adjusting insulin treatment to maintain normoglycaemia in Type 1 diabetes is 
highly desirable, not easily achieved, and particularly safety-critical. 
In this chapter, an evaluation methodology is presented for testing glucose 
controllers in in silico simulation environment. The methodology includes two 
dimensions with the objective to promote the development of satisfactory 
controllers. The testing is first in relation to specific life style conditions (fasting 
and postprandial, for example), and, second, in relation to operating 
conditions such as expected or adverse operating conditions. This provides a 
coherent framework to carry out systematic evaluation proceeding from simple 
(most common) to more complex (less common) scenarios under which the 
system is expected to perform. The methodology helps to identify factors 
affecting the performance measures providing feedback for the development 
of the controller. 
The use of the methodology is exemplified by tuning and evaluating the MPC 
controller presented in section 3.4.4 focusing on testing under fasting 
conditions. 
6.2 Methods 
6.2.1 Simulation Environment 
The simulation environment shown in Figure 6. 1 was described in details in 
Chapter 5 and represents the interaction between the closed-loop 
components. 
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Figure 6. 1: Overview of a simulation (virtual) environment to facilitate tuning 
and testing of glucose controllers. 
The glucose measurement process consisted of a pure technical delay and a 
specific degree of measurement error. 
The environment includes 18 virtual subjects with Type 1 diabetes. 
Differentiation among virtual subjects is achieved by assigning a unique set of 
parameters to the glucoregulatory model as explained in Chapter 5. 
For this evaluation, the intra-individual variability of the glucoregulatory system 
is implemented in the virtual patients by superimposing sinusoidal oscillations 
on model parameters. These include fast oscillations (3h period) and slow 
oscillations (24h period) in combination with a low amplitude (5% of parameter 
value) and a high amplitude (30%). The phase is also drawn from a random 
(uniform) distribution for each parameter. This provides for virtual subjects with 
widely ranging behaviour characteristics. 
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6.2.2 Model Predictive Controller of Glucose Concentration 
The model predictive control (MPC) (178) IS an emerging methodology to 
facilitate control of systems with long time delays and open loop 
characteristics. When combined with adaptive capabilities, it promises to 
tackle successfully problems related to the difficulties encountered in the 
artificial pancreas (AP) development. 
In this study, an MPC-based glucose controller (185) described in detail in 
Chapter 3 is evaluated. The controller has been designed to be used with an 
intravenous and subcutaneous glucose measurement, in combination with a 
subcutaneous insulin infusion of fast acting insulin such as Lispro. 
The "aggressiveness" is a parameter of the MPC controller, which quantifies 
the penalty associated with large changes in the insulin infusion rate (the 
objective function of the dose optimiser contains two factors, one representing 
adherence to target glucose profile and the other is the norm of first 
differences in the sequence of insulin infusion rates). A large value of the 
aggressiveness increases the risk of hypoglycaemia whereas a low level 
results in a too slow normalisation of glucose levels. 
6.2.3 System Tuning 
The simulation environment represents an ideal tool to tune the controller and 
also to investigate the effect of various system set-ups. This is exemplified by 
finding an optimal value for the aggressiveness parameter of the controller 
and by assessing the effect of constraints in insulin infusion particularly the 
maximum infusion rate, see Figure 6.2. 
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Tuning 
Glucose controller Insulin pump 
------------------------------
Aggressiveness Step size Maximum infusion rate Bolus delivery 
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, 
----------_ ... _ •• _------- ______ 1 
Figure 6.2: Simulation environment is instrumental in tuning the controller and 
assisting in the evaluation of settings of other system components such as the 
insulin pump. 
6.2.4 Methodology to Test Blood Glucose Controllers Employing 
Simulator of Glucose Metabolism 
6.2.4.1 Overview 
The methodology evaluates the glucose controller In three (simulated) 
physiological conditions: fasting, postprandial, and life-style (metabolic) 
disturbances such as exercise, see Figure 6.3. 
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Figure 6.3: Glucose controller must be evaluated under different physiological 
conditions. 
In each physiological condition, the concern is with the performance of the 
glucose controller under three operating conditions, expected operating 
conditions (EOC), adverse operating conditions, and system failure, see 
Figure 6.4. 
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Figure 6.4: Overview of the validation methodology for blood glucose 
controllers (see text for details). 
The EOC represents the typical conditions in which the controller is expected 
to work. These include the expected properties of the sensing device, 
properties of the target population, and properties of the insulin delivery 
device. 
The glucose sensor IS characterised by its measurement error, a 
measurement delay associated with subcutaneous glucose sensing (the delay 
is due to, for example, the kinetic properties of the glucose transport between 
85 
Chapter 6: Evaluation of Glucose Controllers in Virtual Environment: Methodology 
and Sample Application 
plasma and the interstitial fluid) (205,206). In the thesis, the model employed 
is by Wilinska et al (135,207), which is presented in detail in Chapter 4. 
The target population is characterised by its inter-subject and intra-subject 
variability. Subjects differ in how much insulin they need (an inter-subject 
variability) which reflects their insulin sensitivity and other parameters of the 
glucoregulatory system. Second, insulin needs vary throughout the day due 
to, for example, diurnal changes in insulin sensitivity (an intra-subject 
variability). 
As mentioned in Chapter 5, the insulin pump delivers insulin according to its 
technical specification (a step-by-step motor) and subject to constraints such 
as the maximum delivery rate and the step resolution. 
The set-up for early clinical testing included intravenous glucose sampling and 
subcutaneous insulin delivery. A 3-5% coefficient of variation (CV) of the 
measurement error was expected, a 3min measurement delay (representing 
time needed to analyse plasma glucose on a bed-side analyser), a 
intra-subject variability (oscillations) of the parameters of the glucoregulatory 
system with a 5% CV and a 3h or 24h period, a 3min step delivery of insulin 
with a resolution 0.1 U/h and a maximum infusion rate 4U/h, and a 15% CV of 
the error associated with insulin delivery. 
Properties of the system components/environment can temporarily deteriorate 
and it is essential to assess the performance of glucose controllers under 
adverse operating conditions. 
In particular, the measurement error associated with the glucose sensor can 
increase or the measurement delay can be prolonged. This also includes an 
increased amplitude of the intra-subject variability of the parameters of the 
glucoregulatory system. 
Our implementation of the adverse operating conditions increased the CV of 
measurement error to 8 % and 1 5% , the measurement delay from 30 to 40 
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min, and the amplitude of the intra-subject variability to 300/0 with an unaltered 
period of 3h or 24h. The measurement delay in the adverse operating 
conditions assumes subcutaneous glucose sampling via extracorporeal open 
flow microperfusion (208) and consists of a 10min physiological delay, a 
20min dead space of the sampling cannula, and an additional adverse 
conditions related 10min delay. 
System failure may have catastrophic consequences. Glucose controllers 
need to have a built-in safety (protection) scheme to deal with exceptional 
circumstances (209) with the objective of minimising the risk of insulin 
overdose and subsequent hypoglycaemia. 
The tests proposed are related to a sensor drift and to an insulin pump 
occlusion. The sensor drift represents the situation where there is a 
progressively increasing bias between glucose measurements and the actual 
glucose levels. If the sensor overestimates actual glucose levels this may lead 
to insulin overdosing. A pump/tissue occlusion lasting several hours may lead 
to the creation of an insulin reservoir in the pump/tissue, which can abruptly 
enter the system. This problem can be exacerbated by the glucose controller 
increasing the insulin infusion during the occlusion period to "counteract" 
increasing glucose concentration. 
6.2.4.2 Assessing Glucose Control 
The glucose control is evaluated using two criteria, see Table 6. 1. The primary 
criterion is the safety of glucose control. The secondary criterion is the efficacy 
of glucose control. The safety criterion is concerned with the avoidance of low 
plasma glucose (hypoglycaemia), the efficacy criterion with the avoidance of 
high plasma glucose (hyperglycaemia). The rationale behind the definitions of 
the two criteria is that of an acute danger such as unconsciousness or coma 
associated with hypoglycaemia, and that of the development and progression 
of microvascular and macrovascular complications of diabetes (limb 
amputations, blindness, renal failure etc), which IS associated with a 
prolonged elevation of plasma glucose. From a clinical viewpoint, the 
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classification adopted in the current chapter is valid but crude, ignoring some 
of the physiological knowledge of the effect of impaired control on short and 
long term complications. It is technically oriented but retains the high level 
assessment of clinical safety and efficacy. The aim is to eliminate algorithm 
with insufficient performance from further testing and to benefit from simple 
criteria to improve iteratively the control strategy. 
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Table 6.1: Definition of safety and efficacy criteria for glucose controllers. 
Grade Fasting conditions Post-prandial state Metabolic disturbances 
such as physical exercise, 
alcohol intake, etc 
Excellent No hypo* AND no serious hypo** as for fasting conditions as for fasting conditions 
Good 
ｾ＠ 5% subjects with hypo AN D as for fasting conditions as for fasting conditions 
no subject with serious hypo 
>. 
...... ｾ＠ 20% subjects with hypo AND as for fasting conditions as for fasting conditions ｾ＠ Satisfactory co 
CI) no subject with serious hypo 
> 20% subjects with hypo OR as for fasting conditions as for fasting conditions 
Unsatisfactory at least one subject with serious 
hypo 
Excellent PG ｾ＠ 6 mM 2 hour PG ｾ＠ 8 mM as for fasting conditions 
>. Good PG ｾ＠ 7 mM 2 hour PG ｾ＠ 9 mM as for fasting conditions u 
co 
u 
ｾ＠ Satisfactory PG ｾ＠ 8 mM 2 hour PG ｾ＠ 11 mM as for fasting conditions w 
Unsatisfactory PG> 8 mM 2 hou r PG > 11 mM as for fasting conditions 
*hypo is defined as 2.0mM < PG ｾ＠ 3.3mM; **serious hypo as PG ｾ＠ 2.0mM 
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6.2.4.3 Safety Criteria 
The safety criterion assesses the safety of the glucose control. This is achieved 
by evaluating the number of virtual subjects who present hypoglycaemia (2.0mM 
< plasma glucose ｾ＠ 3.3mM) and serious hypoglycaemia (plasma glucose ｾ＠
2.0mM) during a relatively short duration Ｈｾ＠ 24h) of virtual tests. 
"Excellent" safety is achieved by avoiding hypoglycaemia and severe 
hypoglycaemia in all subjects. "Good" safety is characterised by a very low risk 
of hypoglycaemia Ｈｾ＠ 5% of subjects with hypoglycaemia) without the presence of 
severe hypoglycaemia. "Satisfactory" safety is aimed to reflect incidence of 
hypoglycaemia with continuous subcutaneous insulin infusion (CSII), the current 
"gold" standard; there are limited comparable data and we set the limits Ｈｾ＠ 20% 
of subjects with hypoglycaemia; no severe hypoglycaemia) more stringently than 
those reported in a study by Renner et al (210) (about 40% subjects experienced 
hypoglycaemia in a day). "Unsatisfactory" safety is characterised by levels of 
hypoglycaemia in more than 20% subjects or by the presence of severe 
hypoglycaemia in one or more subjects. 
The safety criterion is identical for all three "physiological" conditions, i.e. fasting, 
postprandial, and metabolic disturbances. 
It is important to stress that simulated clinical trials are run for 8 to 24 hours and 
thus the safety criterion is defined taking into account the relatively short duration 
of the trials quantifying % of subjects with hypoglycaemia rather than incidence 
of hypoglycaemia per patient year as is standard in longitudinal studies such as 
the Diabetes Control and Complications Trial (DCCT) (210). 
6.2.4.4 Efficacy criterion 
The efficacy criterion evaluates the ability of glucose controllers to achieve 
glucose levels, which are known to avoid diabetes complications. 
In the fasting state, "excellent" efficacy gives glucose levels Ｈｾ＠ 6mM) similar to 
those observed in healthy subjects. "Good" efficacy (plasma glucose ｾ＠ 7mM) 
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was set to resemble the World Health Organisation (WHO) limit for the diagnosis 
of impaired glucose tolerance (211). The "satisfactory" efficacy (plasma glucose 
:5 BmM) corresponds approximately to the best currently available management 
practice as documented by intensive insulin therapy in the DCCT (210). 
"Unsatisfactory" efficacy is that which is less satisfactory, i.e. worse than the 
current best management practice. 
In the postprandial state, the focus is on 2h postprandial glucose, which is widely 
used for the diagnosis of diabetes and in the assessment of postprandial glucose 
control. "Excellent" efficacy (2h plasma glucose :5 BmM/) was adopted to be 
similar to the WHO diagnostic limit of diabetes (211). "Satisfactory" efficacy (2h 
plasma glucose :5 11 mM/) represents a slightly worse control than that observed 
with the best currently available management practice as exemplified by the 
intensive therapy during the DCCT (62). "Unsatisfactory" efficacy represents 
control worse than what is currently available. 
In the conditions of life style disturbances, the efficacy criterion is the same as 
during the fasting conditions. 
6.3 Results and Discussion 
6.3.1 Simulation Environment 
A sample outcome of a simulated clinical trial in a virtual subject is shown in 
Figure 6.5. The test included the digestion of a meal with co-administration of a 
"manually" determined insulin bolus. The closed-loop control commenced 3h 
after the meal. 
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Figure 6.5: Example of glucose control using the simulator. At time Omin, a 
synthetic Type 1 diabetes subject had a meal and received insulin bolus. At 
180min (vertical bar), glucose was artificially raised to 11 mM and the 
subcutaneous insulin infusion was initiated. A model based glucose controller 
calculated the infusion rate every 15 min using intravenous glucose 
measurements also taken every 15 min. 
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6.3.2 System Tuning 
The results of the system tuning are shown in Table 6.2. 
Table 6.2: Tuning controller and insulin pump settings 
Set-up 
1 
3 (J) 
(J) 
Q) 
c 
Q) 
Ｎｾ＠ 5 
(J) 
(J) 
Q) 
L.. 
C> 
C> 7 <t: 
1000 
Maximum infusion rate 4U/h with 
step size 0.2 U/h 
Maximum infusion rate 2U/h with 
step size 0.1 U/h 
Bolus delivery 
Safety 
Good 
Good 
Good 
Satisfactory 
Satisfactory 
Good 
Excellent 
Excellent 
Efficacy 
Good 
Good 
Excellent 
Excellent 
Excellent 
Excellent 
Good 
Good 
In the first instance, the effect of "aggressiveness" was investigated on the 
performance of the controller. The best trade-off was with aggressiveness 5 
(unitless) which gave good safety and excellent efficacy. Higher values of 
aggressiveness maintained excellent efficacy but safety was compromised. 
Lower values of aggressiveness reduced efficacy. 
All future runs with the controller were therefore run with the aggressiveness set 
to 5 (unitless). 
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A close inspection of the data collected during the "aggressiveness" tests 
indicated that some virtual subjects were temporarily infused with insulin rates 
above the upper limit currently employed during the CSII. Clinical considerations 
suggested employing an upper limit of 4U/h and technical considerations of an 
insulin pump to be employed in real clinical trials (to facilitate a fast manual 
change of the insulin pump rate) implied that a 2U/h limit should also be 
considered. The former limit was tested with a reduced step size of 0.2U/h (in all 
other tests a step size resolution was 0.1 U/h) again considering a fast manual 
alteration of the pump rate. 
The limit of 4U/h lead to the same results as the limit-free testing. The 2U/h limit 
improved safety. However, efficacy was reduced due to several insulin resistant 
subjects receiving too little insulin. It was decided to adopt the 4U/h and not the 
2U/h limit for future testing. The step size was set at 0.1 U/h as this was 
subsequently found technically feasible. 
Insulin pumps deliver insulin in m icroboluses 0.5 to 3 min a part. This quantum 
insulin delivery may introduce a discrepancy between the expected and truly 
infused insulin at times when infusion rates change considerably. The 
discrepancy can be avoided by administering insulin not as a continuous insulin 
infusion but as boluses given at the start of the control cycle (in our system, 
insulin rate changes every 15min). The performance of bolus delivery was 
evaluated and gave excellent safety and good efficacy. The efficacy just failed to 
reach the excellent grade. Thus, in purely performance terms, bolus delivery of 
insulin every 15 min appears to be a preferable mode of insulin delivery. This 
feature was not retained as it was considered that a zero fluid flow for 15min at 
the tip of the cannula might increase the risk of an occlusion. 
6.4 Application of the Methodology to Test Blood Glucose 
Controllers on Simulator 
To exemplify the use of the methodology the performance of the model predictive 
controller was evaluated under fasting conditions. The results are shown in 
Table 6.3. 
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Table 6.3: Summary 0 f validation results for model predictive control/er during 
fasting conditions. 
Fasting conditions 
Set-up 
Safety Efficacy 
Expected operating conditions Excellent Good 
0> High measurement error Satisfactory Good c 
:OJ 
m en L. c <1> 
a. 0 Long measurement delay Excellent Satisfactory 0 :2 
<1> "0 C en 0 L. 
<1> 0 
> High intra-subject variability Unsatisfactory Excellent 
"0 
ｾ＠
Sensor drift NO* NO* 
E <1> 
<1> L. 
...... :J 
en 
>- ｾ＠ Pump occlusion Satisfactory Good Cf) 
*Not done 
Under expected operating conditions, the controller achieved excellent safety 
and good efficacy. No hypoglycaemia events were observed. 
This provided the reassurance for subsequent real clinical testing which involved 
nine CSII treated subjects with type 1 diabetes (six females and three males) 
with basal insulin needs of 22.5±7.0 U/day. Subjects received a 40g breakfast at 
8:00 after an overnight fast. From 11 :30 the MPC took control until 19:30 
employing I V glucose measurement and SCi nsulin L ispro infusion (212). The 
clinical study gave similar results to those obtained in the simulation study. The 
similarity of the two sets of results provides support for the validity of the virtual 
environment. This early stage clinical trial employed a simplified setting 
compared to that presented in Chapter 7, section 7.2.4. 
Under adverse operating conditions, the high measurement error reduced safety 
while maintaining efficacy. The reduction in safety can be at least in part 
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attributed to "false-positive" hypoglycaemia events, i.e. plasma glucose above 
the hypoglycaemia threshold can be "measured" below the threshold after 
adding the measurement error and this situation will be exacerbated with an 
increased measurement error. The long measurement delay reduced efficacy but 
still achieved the satisfactory grade. The high intra-subject variability was the 
only set of conditions with unsatisfactory safety. This was due to the presence of 
one severe hypoglycaemia (out of 36 virtual tests). This indicates that large 
variations (300/0 of nominal values) in individual parameters are difficult to deal 
with by the glucose controller. 
Of the two types of the system failure, only the pump occlusion was tested. The 
2h 0 cclusion gave satisfactory safety and good efficacy a s assessed by P ost-
occlusion plasma glucose over a period of 5h. This was an important observation 
as the pump occlusion is not a rare event. Modern insulin pumps are equipped 
with pressure sensors to detect the occlusion but an additional safety margin is 
beneficial. The sensor drift has not been tested as limited information is known 
about the glucose sensor being developed for this particular version of the 
artificial pancreas. 
6.5 General Discussion 
The development and testing in a simulation environment is an appealing and 
worthwhile strategy to lower costs and to reduce the development time. The 
validity of the approach lies in the creation of a virtual environment faithfully 
representing real world conditions. In the medical field, the richness of the 
environment has to reflect the variability between individuals, variability within 
individuals, and characteristics of the technical components such as the 
measurement error. The simulation environment was presented in detail in 
Chapter 4 and Chapter 5 and designed in such a way that the different 
methodological components can easily be addressed. 
In this chapter, the concern is with the development of a testing methodology for 
glucose controllers. Several notes related to the development and validation of 
the virtual environment apply. First, the virtual development should be based on 
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real data. It is clear, however, that there will be components for which our 
knowledge is incomplete and/or inconsistent. For example, the pump 
characteristics may change and alleviate some of its limitations and new 
knowledge may support some amendments in the methodology describe here. 
This requires qualified guesses to be made about underlying probability 
distributions of some parameters and properties. Second, the validation of the 
virtual environment is an important issue but this can normally be resolved only 
after real clinical tests have been conducted. 
The methodology presented in this chapter holds general applicability for other 
medical systems where the need for adaptive techniques in a varying 
environment is applicable. The evaluation is divided first according to the life 
style conditions starting with simple to more complex (or most common to less 
common) under which the application is planned to be used. This reflects that 
these conditions may require different definition of evaluative criteria. The 
second dimension of the evaluation is related to the settings of physiological and 
technical parameters of the system (stressing that the human is part of system) 
proceeding from the normal (expected) operating conditions to those which can 
be classified as the system failure. An important part 0 f the methodology is a 
definition of the evaluative criteria. In the medical domain these neatly divide into 
safety (is the system safe to use) and efficacy (does the system achieves its 
primary goal). 
6.6 Conclusion 
A methodology has been developed to test glucose controllers in a simulated 
(virtual) environment. The methodology is instrumental in anticipating the results 
of real clinical tests for different physiological conditions and for different 
operating conditions. The thorough testing in the virtual environment reduces 
costs and speeds up the development process. The following chapter is 
presenting a methodology to assess glucose control from a clinical point of view 
and its use for the simulator validation. 
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7 Clinical Assessment of Control and Simulator Validity 
7. 1 Introduction 
Chapter 6 described an evaluation strategy to support in silica development of 
glucose controllers. The strategy provided a framework for systematic 
classification of the performance of glucose controllers for a range of 
physiological conditions and different types of the operating environment. The 
objective of the evaluation strategy was to prevent the deployment or even 
clinical testing of substandard controllers. 
From a clinical view point, the classification adopted in Chapter 6 is inevitably 
crude and ignores some of the physiological knowledge of the effect of impaired 
control on short and long term complications. 
National and international bodies have compiled such knowledge and have 
provided guidelines suggesting threshold values. This includes organisations 
such as the America Diabetes Association (ADA), Diabetes U.K, the American 
Association of Clinical Endocrinology, and the World Health Organisation (WHO). 
First new criteria are defined to assess the performance of glucose controllers. In 
this case, a purely clinical viewpoint is a dopted and the criteria are based 0 n 
therapeutic guidelines. As there are minor inconsistencies among guidelines 
from different organisations, suggestions proposed by the ADA are adopted. 
The system introduces six grade values A to F to describe the level of control 
and the required therapeutic action during fasting and postprandial conditions. 
The outcome of grading is the quantification of time spent in each grade and is 
illustrated through individual examples. 
Secondly, the grading system is used to compare the synthetic subjects and real 
subjects with Type 1 diabetes with main characteristics shown in Table 7.1. 
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Table 7.1: Characteristics of real and synthetic subject groups 
Real subjects Data used to generate 
synthetic su bjects 
Number of males 8 11 
Number of females 4 7 
Age (years) 41±11 35±7 
8MI (kg/m2) 24±2 25±3 
Duration of diabetes 24±12 (years) 16±9 
Both subject groups had similar basal insulin needs with a wider variability in the 
synthetic subject group (14.7±3.9 vs 14.2±6.0 mU/kg/h; real subjects vs 
synthetic subjects; mean±SD; range 9.3-20.9 vs 5.0-26.0 mU/kg/h). The prandial 
needs were lower in the synthetic subject group (0.7±0.3 U/10g CHO; range 
0.3-1.1) than in the real subject group (1.6±0.9/10g CHO; range 0.5-3.4 /10g 
CHO). Both subject groups underwent a similar trial and were controlled over 
24h by the MPC described in section 3.4.4. 
Although examples of individual control are provided, the comparison among the 
two subject groups is based on population rather than individual basis and 
serves to demonstrate the validity of the simUlation environment. We employed 
the average glucose profile and average indices of glucose control in the 
comparison. 
The primary aim of in silica testing is to replace, where possible, clinical testing. 
Similarity of the level of control would support the clinical notion of validity. 
Apart from clinical validation, other validation modalities could be considered. 
This includes t he validation of model subsystems, intra-subject variability, and 
inter-subject variability. These validation modalities are not considered here. 
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7.2 Methodology 
7.2.1 Clinical Criteria and Setting 
Controlling glucose profile is the essential goal of insulin therapy. The focus is to 
limit glucose excursions while avoiding hypoglycaemia. Ideally, a glucose profile 
should be reproduced by limiting postprandial glucose excursions and achieving 
fasting glucose levels within a narrow range to avoid and/or reduce the long term 
complications. 
By employing clinical criteria to assess the control of the glucose profile it is 
possible to demonstrate the strengths and weaknesses of a glucose controller 
and its ability to achieve glucose control. 
7.2.2 Definition of the Clinical Criteria 
A grading system with grades A,B,C,D,E, and F, see table Table 7.2, was 
introduced following the approach broadly adopted by Clarke et al (213) to 
assess clinical utility of alternative sites/devices for glucose measurements. The 
grades describe, in a quantitative fashion, the level of ambient glucose reflecting 
the need or lack or need of a therapeutic intervention. Grade A corresponds to 
the glucose level within the tight physiological range without the need for a 
corrective action. Grade F corresponds to life threatening control with the need 
for an immediate action. 
Grading of ambient glucose levels depends on physiological status. At present 
we considered two, postprandial and fasting conditions. For each condition, 
grading is based on threshold glucose values, see Table 7.3. The postprandial 
condition is defined from 15 min to 180 min following meal ingestion. The fasting 
condition is that outside the postrandial condition. 
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Table 7.2: Qualitative grading of glucose control 
Qualitative grade 
A 
B 
C 
o 
E 
F 
Control efficacy level/Action 
recommendation 
Excellent control/No action required 
Good control/No action required 
Sub optimal control/Action recommended 
Poor control/Action required 
Very poor control/Immediate action required 
Life threatening control/Require assistance 
Table 7.3: Grading for fasting and postprandial conditions. 
Plasma glucose Fasting Postprandial 
(mM) Conditions Conditions 
$2.8 F F 
$3.3 E E 
$4.4 C 0 
$6.1 A B 
$7.2 B A 
$7.8 C A 
$10.0 0 B 
$13.9 0 C 
$25 E 0 
>25 F F 
7.2.3 Explanatory Notes 
This section justifies the selection of threshold values adopted in Table 7.3. 
7.2.3.1 Fasting Conditions 
The plasma glucose value at 2.8mM or below represents severe hypoglycaemia 
(16) which is likely to require an external assistance (214) and is potentially life 
threatening. The plasma glucose level 3.3mM represents a hypoglycaemia 
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threshold (16) , see for example a study comparing the multiple daily injections 
and the continuous subcutaneous insulin infusion (76). A subject should still be 
able to counteract the hypoglycaemia by an immediate glucose intake. 
Below the plasma level of 4.4mM, hypoglycaemia threshold is close and 
although the subject may not feel any discomfort (215), an action from the 
patient may be required as a prevention. 
In the fasting conditions, the target plasma glucose for very good control is 
between 4.4 and 6.1 mM. The lower bound has been used, for example, by 
pregnant women with Type 1 diabetes (216). The upper bound has been chosen 
as a limit of normality by the ADA (30) and the WHO. 
In fasting conditions, plasma glucose level up to 7.2mM is outside the normal 
range in a healthy subject but still low enough to be considered good and is the 
preprandial maximum plasma glucose concentration recommended for adults 
(217). 
Plasma glucose above 7.8mM increases the risk of complications. The threshold 
is employed by the WHO and is also often associated with the elevated glucose 
in the postprandial condition (30). Therefore, adjustment should take place to 
optimise the glucose control. 
Glucose above 10mM represents poor control which requires a control action. 
Glucose above 13.9mM increases further the risk of complications and an 
immediate action is required to prevent the appearance of ketones. However, the 
life of the subject is not in an immediate danger. Plasma glucose of 25mM is a 
diagnostic criterion for diabetes ketoacidosis which can lead to a diabetic coma if 
not treated. 
At plasma glucose of 25mM and above an external assistance may be required 
such as hospitalisation due to the diabetic coma. 
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7.2.3.2 Postprandial Conditions 
Threshold employed for the postprandial conditions require a slightly different 
approach as glucose values can be elevated even in healthy subjects. 
The two lower thresholds are similar to those adopted for the fasting conditions. 
Plasma glucose below a threshold of 4.4mM in the postprandial conditions is 
likely to result in insulin overdosing which could lead to an accelerated 
downward trend when glucose appearance from the gut is completed. 
To a lesser extent, a similar consideration applies to a glucose level below 
6.1 mM explaining the choice for its B grading. 
In the postprandial conditions, plasma glucose in healthy subjects is elevated 
and glucose levels up to 7.8mM can be observed but the endogenous surge in 
insulin secretion at t he meal time limits the transient glucose excursions. The 
plasma glucose level of 7.8mM represents the threshold separating normal and 
impaired glucose tolerance (30) but represents an excellent control. Insulin 
dosing is preventing the large glucose excursion while allowing glucose to rise 
providing a safety margin to protect from a potential hypoglycaemia. 
Plasma glucose of 10mM is recommended by t he ADA a s the peak p ostmeal 
glucose excursion and is therefore graded as a good control. Above the 
threshold of 10mM, plasma glucose is referred to as suboptimally controlled. 
For the same reasons but to a larger extent, plasma glucose above 13.9mM is 
classified as poorly controlled. Above this level, the ketones start to be present 
and a control action from the subject is required. 
Above plasma glucose of 25mM, the risk of diabetic coma is greatly increased. 
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7.2.4 Clinical Trial Setting 
The single centre clinical trial (University Hospital, University 0 f G raz, Austria) 
studied 12 subjects with Type 1 diabetes (duration of diabetes 24±11 years) 
aged 21 to 64 years; BMI 24±2 kg/m2 . The subjects were well controlled (HbA1c 
7.3±0.9% ) and were treated by continuous SUbcutaneous insulin infusion (CSII) 
with fast acting insulin. Their insulin needs were 20±6 U/day for the basal 
infusion and 22±6 U/day for the prandial bolus. 
The subjects arrived at the clinic at 14:00 and left at 22:00 the next day. After 
arrival, subjects were normalised to a target plasma glucose level of 5.5-6.6mM 
with intravenous insulin and glucose until 17:00. Then the 
intravenous-intravenous route was discontinued and subjects were switched 
onto the usual insulin pump administrating fast acting insulin lispro (Humalog, Eli 
Lilly). At 18:00 dinner was ingested and a standard prandial bolus was 
administrated. At 19:30 an automated insulin delivery driven by the Model 
Predictive Control (MPC) was initiated and lasted overnight followed by a 
breakfast at 7:00 (60, 72, or 84g carbohydrates (CHO)), lunch (60, 72, or 84g 
CHO) at 12:00 and dinner (48, 60, or 72g CHO) at 18:00. The meal choice was 
based on the usual daily caloric intake of a subject. 
The insulin infusion was driven by the MPC over a 26.5 hour period with 
intravenous plasma glucose measurements and insulin pump rates adjusted 
every 15m inutes. At the time 0 f a meal, t he algorithm was provided with the 
subject's estimated carbohydrate intake and an insulin bolus generated by the 
MPC was administrated at the time of meal ingestion. A 10g oral glucose would 
be given in case of hypoglycaemia defined as a plasma glucose measurement at 
or below 3.3mM. To simulate subcutaneous glucose measurements, the plasma 
glucose measurements were presented to the MPC with a 30min delay. 
One subject presented abnormal insulin needs and was removed from the 
comparison. 
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7.2.5 Simulated Trial 
During the simulation, the automated control covers the same time span (26.5 
hours) as during the clinical trial. The simulation started at 17:00. Similarly to the 
clinical trial, at 18:00 a dinner and in individually determined bolus were given. At 
19:30, the MPC took over the insulin administration. Breakfast, lunch, and dinner 
were taken at the same time as during the clinical trial (7:00, 12:00 and 18:00); 
the C HO quantities were 40, 70, and 60g C HO, respectively. Plasma glucose 
measurements were obtained every 15 minutes and were made available to the 
MPC with a 30 minutes delay. Insulin boluses at the meal times were also 
generated by the MPC. 
The average insulin needs were 25±10 U/day for the basal insulin and 27±15 
U/day for prandial boluses, see Chapter 5. 
Due to abnormal insulin needs and the kinetics of glucose after meal ingestion, 
subject 9 was excluded from the comparison. The remaining 17 synthetic 
subjects were compared against 11 real subjects with Type 1 diabetes. 
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Test setti ng 
Si mulated glucose Measured glucose 
Figure 7.1: The approach to compare the simulator with data collected during a 
real clinical trial. 
7.3 Results 
7.3.1 An Example Use of the Criteria 
Glucose controls in two synthetic subjects are presented in Figure 7.2 and 
Figure 7.3. The former figure presents a profile of a well controlled subject and 
the latter figure a profile of a suboptimally controlled subject. The qualitative 
criteria for the two profiles are shown in Table 7.4 and Table 7.5. 
106 
Chapter 7: Clinical Assessment of Control and Simulator Validity 
16 
14 
ｾ＠ 12 
E 
-a 10 
:oJ 
ｾ＠
.-
c 
ｾ＠ 8 
c 
8 
<1> 6 (J) 
8 
::J 
(!) 4 
o 
20:00 
,. 10 
ｾ＠ 8 
! 
r 6 
----------1 
4 
0 
04:00 12:00 20:00 
Time 
. 180 
_ ｾ＠ 160 
:::> 
en 
<1> 140 (J) 
-::J I 
"0 -.. ::J 
CO 
. 120 E 
-.. 
-
, 
c ｾｩ＠ 0 2. f 100 :.;:J co 
L-
(J) , C <1> ｾ＠ 80 ｾ＠ro L- c 
c 8 0 
'iii 60 c ::J 
...... ::J 
C (J) 
c 40 .E 
::J 
(J) 
c 
20 
0 
Figure 7.2: Plasma glucose profile (smooth solid line) as an example 0 f good 
control in synthetic subject 14. 
Table 7.4: Percentage time spent in grade A to F for fasting and postprandial 
conditions, and both conditions for a well controlled subject 14. 
Conditions A B C 0 E F 
Fasting 28.0 71.8 0.2 0.0 0.0 0.0 
Postprand ial 49.9 50.1 0.0 0.0 0.0 0.0 
Fasting and Postprandial 36.1 63.8 0.1 0.0 0.0 0.0 
Subject 14 is representative of very well controlled subjects with almost 100% of 
the plasma glucose levels falling into A and B grades. Such a subject is less 
likely to develop complications due to elevated glucose. Postmeal glucose 
excursions are within the normal range while the risk of hypoglycaemia is limited 
by maintaining glucose levels above 4.1 mM. The performance in this case is 
excellent. 
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Figure 7.3: Plasma glucose profile (smooth solid line) as an example of poor 
control in synthetic subject 17. 
Table 7.5: Percentage time spent in grade A to F for fasting and postprandial 
conditions and both conditions for a suboptimally controlled subject 17. 
Conditions A B C D E F 
Fasting 0 40.2 30.4 29.4 0 0 
Postprandial 4.9 42.7 52.4 0 0 0 
Fasting and Postprandial 1.8 41.3 38.7 18.7 0 0 
The second example illustrates the difficulties encountered with an insulin 
resistant subject. The glucose profile never falls in Grade A in the fasting period 
and less than a half of the time it falls in the Grade B leaving about 60% of the 
fasting time in Grade C and D. In the postprandial conditions, a considerable 
amount of time is spent above the ADA peak limit of 10mM. Consequently, more 
than 50% 0 f t he postprandial time iss pent in Grade C. Reflecting the clinical 
implications of the elevated glucose levels this subject is clearly a t the risk of 
developing long term complications. The MCP did not control this subject well. 
108 
Chapter 7: Clinical Assessment of Control and Simulator Validity 
The previous examples suggest that more insulin resistant subjects attain poorer 
control. Table 5.7 shows the fasting and meal related insulin needs for each 
subject. These values were correlated with the percentage of time spent in very 
good and good bands (A+B), see Table 7.6. 
Table 7. 6: Correlations between basal and prandial needs with time spent in 
(A +8) bands during fasting, prandial and combined conditions. 
Basal needs Prandial needs 
A+B in fasting state -0.76 -0.43 
A+B in postprandial state -0.51 -0.31 
A+B in Fasting and Postprandial combined -0.75 -0.44 
There is a clear association in the level of basal insulin needs and the level of 
control. The higher the basal needs, the less time is spent in the (A+B) bands. 
Thus the controller achieves less favourable control in more insulin resistant 
subjects. 
7.3.2 Comparison Assessment 
Employing the grading system presented in section 7.2.2, the glucose control 
was evaluated by calculating the time spent in each grade. Fasting and 
postprandial periods were considered separately. The overall performance was 
considered by combining the two periods. 
Figure 7.4 shows the plasma glucose profiles during the clinical and simulated 
trials. 
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Figure 7.4: Plasma glucose profiles during the clinical and simulated trial 
(mean±SE). 
The glucose profile can be divided into five periods, the first postmeal period, the 
overnight fast, and the following three postmeal periods. 
A mismatch was present following the ingestion of the first meal (first dinner) due 
to initial conditions (data not shown). The start of the comparison between the 
simulated and clinical trial is at 645min (585min after the first dinner) when 
plasma glucose during the simulated trial was normalised. During the overnight 
fast, i.e. from 645 to 1140min, the simulated glucose profile is less oscillatory. 
Following the breakfast at 1140min, the two glucose curves reach their maximum 
at a similar time. However, a peak difference of 1.5mM is present. This is greater 
than the difference of 0.5mM prior to the breakfast. Both curves are decaying in 
a similar fashion. Glucose profiles reach a fairly similar level prior to the lunch. 
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Following the lunch at 1500min a second glucose excursion IS present. 
Compared tot he breakfast, the plasma glucose excursion is less pronounced 
during the clinical trial and very similar during the simulated trial. The initial part 
of the excursions shows a very good level of comparability and again an identical 
time to peak. However, the simulated excursion has a slightly higher peak. A 
mismatch occurs during the decays. During the clinical trial a short term plateau 
is observed followed by a fast decay whereas during the simulation trial a 
monotonic decay is observed. Nevertheless, the glucose concentration prior the 
second dinner is identical in both trials. 
The second-dinner postprandial profiles have a similar nadir but the time-to-peak 
is delayed during the clinical trial and is followed by a fast decay. 
The grading system described in the present Chapter was used to classify the 
level of control during the fasting and postprandial periods, see Figure 7.5. 
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The upper panel of Figure 7.5 compares the fasting periods. The results reflect 
the discrepancies of the two profiles characterised by a better control during the 
simulated trial. This is mainly due to the differences in the overnight period. 
The middle panel presents the grading describing the postprandial period. A 
good match reflects the absence of large differences between the two trials. 
The lowest panel compiles grading from both fasting and postprandial 
conditions. A good match is again observed. 
Importantly, both studies show a near to zero time spent in Grade E and a total 
absence of Grade F indicating the absence of extreme high glucose or serious 
hypoglycaemia values. 
7.4 Discussion 
The criteria defining the various grades are based on present recommendations 
and recent criteria of hypoglycaemia. However, the recommendations have been 
evolving with new knowledge and should therefore be seen as a valuable but 
dynamic tool. In particular, the question of the utility of controlling postmeal 
excursions is still under debate and the peak limit of the ADA (218) was not 
present in the ADA recommendations for 2002 (219). 
The separation of fasting and postprandial conditions has resulted in the use of 
different evaluation criteria for the two conditions. The respective contribution of 
the two conditions to the diabetes complications is under debate as various 
studies have presented different results (220-223). Fasting and postprandial 
hyperglycaemias are suspected to induce different types of complications. 
Microvascular complications tend to be more associated with elevated FPG 
(224,225) whereas macrovascular seems predominantly linked to high 
postprandial glucose (225-227). 
A major obstacle to limit elevated glucose concentrations is an increased risk of 
hypoglycaemia events as evidenced by the Diabetes Control and Complications 
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Trial (DCCT) (228) and other studies (229). Hypoglycaemia is an acute life 
threatening condition and the use of continuous glucose sensing have evidenced 
that a good HbA 1 c accompanied by near normal premeal plasma glucose 
concentrations are not enough as shown by the prevalence of prolonged 
hypoglycaemia in children (16). Moreover hypoglycaemia is a major cause of 
death among subject with Type 1 diabetes. 
Another critical aspect of glucose control is an individual adaptation of treatment 
goals which is included in the ADA recommendations (230). This limits our 
approach to the evaluation. In order to be in line with the recommendations, a 
comparison of the personalised goals and actual glucose profile would have to 
be performed. 
A real system is more complex compared to a model. The question which 
emerges is whether the approximation by the model retains enough of the 
system characteristics so that it can be used for its intended purposes. 
The aim of the evaluation in the present chapter is to demonstrate the 
usefulness of the simulator to assess the performances of glucose controllers As 
opposed to validation principles (186), which are employed in model 
development, the concern here is the clinical validity of simulations. 
The early part of the glucose profile is excluded from the evaluation. The clinical 
protocol allowed corrective actions to provide a "clean" start. The corrections 
were based on the intravenous route. This resulted in well controlled glucose 
levels compared to the simulation which was characterised by large excursions. 
The insulin was individually chosen and aimed at avoiding hypoglycaemia. 
Intravenous corrective actions were not executed. It is important to note that 6 
out of the 11 real subjects experienced hypoglycaemia following the first dinner. 
Therefore, additional oral glucose had to be given suggesting an over delivery of 
insulin. The ensuing fasting period which is characterised by a more elevated 
and oscillatory glucose pattern during the clinical trial could be explained by the 
oral glucose input which represents another disturbance to the system and also 
by hypoglycaemia counteregulation causing a rebound in the glucose trajectory. 
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However, the hypoglycaemia occurrence did not affect the glucose profile. 
Following hypoglycaemia, t he average glucose was virtually identical over the 
post dinner to pre breakfast period, see Table 7.7. Glucose variability as 
measured by J-index (231) did not differ among the two groups, see Table 7.7. 
Table 7.7: Plasma glucose level and oscillation characteristics following first 
dinner and preceding first breakfast (mean±SO). 
Subjects who did not experience hypoglycaemia 
(N=5) 
Subjects who experienced hypoglycaemia (N=6) 
Plasma 
glucose 
(mmol r1) 
6.95±O.89 
6.79±1.21 
J-Index 
(unitless) 
20.12±4.10 
20.98±5.33 
Another important factor is related to the data accessible to the MPC. During the 
clinical trial subjects came several hours prior to the start of the automated 
control. This provided ample data for the controller which has been designed to 
use up to 6 hour of the past data. During the simulated set-up, the data are 
available only for 150min prior to the start of the automated control as the 
simulation started 60min prior to the first dinner. 
Because of the difference in the initial conditions, the comparison during the 
fasting conditions presented differences. Nevertheless, plasma glucose prior to 
the breakfast was similar with about O.5mM difference. The underestimation of 
the peak following breakfast ingestion is likely to be due to the smaller CHO 
content during the simulated trial. Glucose excursions during lunch and dinner 
are also similar. 
During the simulation, the characteristics of the glucose excursions are identical 
for the three meals. During the clinical trial, lunch and dinner resulted in delayed 
and lower glucose peaks. This can be explained by differences in meal 
composition among the breakfast, lunch, and dinner. The breakfast was usually 
hyperglucidic and therefore likely to be quickly absorbed. 
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7.5 Conclusion 
Clinically relevant criteria have been designed and employed to assess glucose 
profiles in the fasting and p ostabsorbative states. The criteria can be used to 
evaluate the glucose control by glucose controllers. The criteria were used to 
compare the control in synthetic subjects and in subjects undergoing clinical 
testing with the MPC controller. This served two purposes. First, the ability of the 
MPC to control glucose was evaluated from the clinical viewpoint. Second, the 
comparison between in silica and clinical testing has facilitated the validation of 
the simulator. 
Although the glucose profiles exhibit some differences especially during the 
overnight fast, the simulated profile is of clinical validity. The differences can be 
explained by the differences in the initial conditions and the difference in meal 
intake. 
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8 General Discussion and Conclusions 
8.1 General Discussion 
The thesis has two major objectives. The technical objective consist of creating a 
simulation environment representing a model of a subject with Type 1 diabetes 
treated by continuous subcutaneous insulin infusion (CSII) and incorporating 
models of the subcutaneous measurement process and the insulin pump. To 
represent a variety of metabolic profiles a group of 18 virtual subjects was 
generated with the aim to provide a tool, which combined with an appropriate 
methodology, can facilitate the development of an extracorporeal artificial 
pancreas (AP). The clinical objective was to employ the simulating environment 
to evaluate the performance of a specific glucose controller resorting to clinically 
motivated safety and efficacy criteria. 
In the last decade, the treatment of Type 1 diabetes has made a tremendous 
progress, but the problem of optimising insulin therapy remains. The Diabetes 
Control and Complications Trial (DCCT) (1) has demonstrated benefits of tight 
control through intensive therapy. This required large resources limiting its large 
scale application. An automated insulin delivery system, the so called "artificial 
pancreas", could provide means to improve glucose control in a spectrum of 
subjects with Type 1 diabetes. 
The approaches to the AP can be divided into two main categories. An 
implantable AP provides several advantages by a voiding delivery and sensing 
delays and retaining a more physiological insulin profile. However, considering 
the long term safety aspects, it is more appropriate to focus on an extracorporeal 
AP. Implantable insulin pumps still await wider use. 
External insulin pump systems are now mature and represent an excellent 
minimally invasive insulin delivery (76,79,232) but are associated with a delay in 
insulin appearance. Moreover the subcutaneous route demands the availability 
of an accurate and long term subcutaneous glucose sensor. Such a device is still 
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not commercially available but the existing products and the extensive research 
in this field give a real hope for the near future. 
Medical treatment delivery systems are subject to rigorous safety evaluation. As 
clinical safety and efficacy need to be clearly demonstrated there is a need for 
extensive clinical trialling at considerable financial, human, and time costs. 
Simulations and in silico testing have already been adopted by the 
pharmaceutical industry to optimise and predict the outcome of clinical trials to 
reduce financial burden involved in the development of new drugs. Similarly, the 
approach can be employed in the development of medical devices. 
As seen in Chapter 3, the concept of a simulated clinical trial to evaluate an 
automated insulin delivery is not new. Many studies have been conducted but 
usually did not include the subcutaneous route resorting to simpler setting using 
the intravenous route or did not adopt a systematic and extensive evaluation 
strategy. 
This fuelled the need to develop a complete testing platform for a 
subcutaneous-subcutaneous system. During the development of a simulation 
environment described in Chapter 5 representing the closed-loop system, in 
which the patient has a central role, the importance of the sources of uncertainty 
and the noise from the measurement process were reflected on, together with 
the pump inaccuracies, and most importantly the between and within subject 
variability. 
The in silica testing phase for the development of an AP requires an evaluation 
strategy. This was defined inC hapter 6 , w here asystematic approach tot est 
control algorithms is presented. The approach offers a clear map of the different 
issues to be tested. However, its universal application is limited. These 
limitations are related tot echnical properties 0 f the pump or t he sensor. They 
also relate to the assumptions employed to generate parameters of synthetic 
subjects. 
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In Chapter 7, clinical criteria were defined to assess the performance of glucose 
controllers taking into account fasting and postprandial conditions. The grading 
offers a qualitative assessment of the overall performance of glucose control and 
employs six grades ranging from Grade A (best control) to Grade F (worst 
control). 
The mapping of levels of glucose to the grades is different for the fasting and 
postprandial conditions. This is justified by the fact that transient elevated 
glucose levels during the postmeal phase are acceptable as elevated glucose is 
also present following meals in healthy subjects. 
The cut-off plasma glucose values defining the mapping procedure were chosen 
to reflect the current standards of glucose control suggested by the American 
Diabetes Association ADA and employed in a number of studies for evaluation of 
glucose control. This underpins the acceptance and credibility of the grading by 
health care professionals as opposed to the criteria presented in Chapter 6, 
which were aimed to provide information for the technical development. 
In Chapter 7, the validity of the simulator is assessed comparing results from a 
simulated trial to these obtained during a real clinical study employing the 
grading system. The simulated trial shows the ability of the MPC to achieve safe 
glucose levels throughout the trial as demonstrated by the absence of the time 
spent in Grade F and virtually no time spent in Grade E. This has been 
confirmed by the clinical study. 
The origin of the discrepancies between the simulated and clinical trials is due to 
the differences in the initial conditions and the differences in meals contents. 
Nevertheless glucose levels prior to each meal intake are comparable. 
The glucose monitor needs to present certain characteristics to be used 
successfully in a closed-loop glucose control system by providing frequent 
measurements with a sufficient accuracy and stability over time. It has been the 
focus of extensive research for decades and represents a major obstacle for the 
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development of an extracorporeal AP (233). An increasing number of research 
approaches and results indicate a significant progress toward its realisation. 
8.2 Achievements of Objectives 
This section outlines the achieved objectives. The structure echoes the 
objectives and is therefore divided into technical and clinical objectives. 
The technical achievements are: 
• Models have been successfully developed to achieve a representation of 
a subcutaneous-subcutaneous controlled system which can be used as a 
simulating environment to test algorithm to control glucose in Type 1 
diabetes subjects; 
• 18 subjects were generated on the base of real clinical data and informed 
probability distribution. The virtual subjects represent a population with 
wide metabolic profile; 
• The subcutaneous-subcutaneous system was scrutinised and a 
methodology to test performance of glucose controllers in terms of safety 
and efficacy was defined; 
• The simulator validity was evaluated uSing clinical trial employing 
subcutaneous glucose measurements and subcutaneous insulin infusion. 
It was shown to be useful for the development of a model predictive 
controller. 
The clinical achievements are: 
• Simulation runs have demonstrated the wide range of metabolic profile of 
the virtual subjects reflecting the actual variability of insulin needs; 
• Suggested guidelines from the ADA were compiled and organised and 
120 
Chapter 8: General Discussion and Conclusions 
criteria used in various studies to establish qualitative criteria to evaluate 
glucose control during trials with the AP; 
• The defined criteria were employed to appraise the simulator's validity. 
8.3 Future Work 
Certain parameters were drawn from probability distribution. Models and/or 
methods could be developed to estimate parameters from data collected 
during clinical tests with the AP to provide means to generate additional 
subjects. 
The parameter variation is partly based on informed probability distributions 
and designed to represent a variety of metabolic profiles and behaviour. 
However the variation does not represent some of the known patterns of the 
metabolism found in humans. For example, the dawn phenomenon was not 
specifically reproduced. 
The methodology was adopted and comparisons were made employing a 
single algorithm, the MPC. Others algorithms could benefit from our testing 
approach. 
Subjects with Type 2 diabetes are mostly treated by diet and oral agents. 
However, some studies have suggested to use CSII to treat the disease (14). 
An extension to Type 2 diabetes by incorporating a model of insulin secretion 
could facilitate testing of controllers in Type 2 diabetes. 
Finally the benefits of tight glucose control in critically ill patients have been 
clearly demonstrated and the extension of the simulation environment to 
encompass subjects in the intensive care units could facilitate the evaluation 
of different treatment strategies. 
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Appendix A 
A. Glucose Profile in 18 Synthetic Subjects Controlled 
byMPC 
Appendix A shows glucose control using the simulation environment in 18 
synthetic subjects. Plasma glucose is represented by the solid smooth line, the 
interstitial glucose with a 5%) measurement error sampled every three minutes is 
represented by the solid ragged line, the insulin infusion rate is represented by a 
piecewise constant solid line, and the insulin boluses are represented by solid 
bars at meal times ingested at 840, 1140 and 1500min and consisting of 40, 70, 
and 60g carbohydrates (CHO), respectively. 
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Figure A. 1: Simulation of subject 1. 
157 
Appendix A 
20 
19 
18 
17 
16 
:1. 15 :::::, 
0 14 E 
E 13 ......, 
fI) 12 c:: 
0 11 .... 
ro 
... 10 
-c:: 
C> 9 (.) 
c:: 8 0 () 
<V 7 
I/) 
6 0 (.) 
ｾ＠ 5 (!) 
4 
3 
2 
1 
15 
14 5 
14 B5 
125 
12 
11 5 
11 ,-. 
10.5 :E 
10 2-
ｾＵ＠ Q: 
85 ----a :E 
7.5 2. 7 If) 
6.5 :::; 
6 
5 5 
o 
.CJ 
c:: 
5 :::; 
ＭｾｾﾷﾷｲＭＱＴ＠ 5 If) 4 c:: 
3 5 
3 
2 5 
2 
1 5 
1 
0.5 
0 ｾＭＭｾＭＭｾＭＭｾｾｾｾｾｾＭＭｾｾｾｾｾｾＭＭｾＭＭｾｯ＠
0 200 400 600 800 1000 1200 1400 1600 1800 2000 
time (min) 
Figure A.2: Simulation of subject 2. 
158 
Appendix A 
20 
19 
18 
17 
16 
=r 15 :::::. 
0 14 E 
E 13 . ....., 
v, 12 c: 
0 11 ..... 
t'O 
.... 10 ..... c: (1) 9 (.) 
c: 8 0 
<.> 
('.) 7 
I/) 
6 0 (.) 
:::i 5 
<.9 
4 
3 
2 
1 
15 
14 5 
14 
135 
13 
12 5 
12 
11 5 
11 ---
10 ｾ＠ .c: :) "'-. 
10 2 
95 ｾ＠
9 
8 5 8 ｾ＠ＢＷｾ＠ ::j 
! ｾ＠
7 (J) 55 :::i 
r-. 
;t ｾ＠
o 
.0 
Ｚｴｾ＠ c 
:t :::i 
----- 45 (J) 
'"' c ｾＵ＠
2 5 
2 
1.5 
1 
o 5 
0 ｾＭＭｾｾｾｾｾｾｾｾｾｾＭＭｾｾｾｾｾｾＭＭＭＭｾｾｾｏ＠
0 200 400 600 800 1000 1200 1400 1600 1800 2000 
time (min) 
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B. Simulator Simulink Block Diagrams 
This Appendix contains the simulator Simulink schematic diagrams of a closed 
loop insulin delivery system employing subcutaneous measurements and 
subcutaneous insulin delivery. 
175 
Appendix B 
l'fLV-¢<1j------________ _ 
L:.)--__ ｾＭＭＭＭＮＮＮＬ＠ Jr,! ｾｾｩｾｕＮｩｴ｟｟ＭＭＭＭＭｾ＠
ｾｾｩｴＮＭｊＭＭｉＺＺＭ｣＠ ----.. 
'----------.. : '"n 
'------------.... , .... , :-
L........ _________ ｾＬＭＮ＠ O.t· ｴ｟｟ＭＭＭＭＭＭＭＭＭＭｾ［ＺｯＺＭＺ＠ -',., ［ｾＺＺ＠ .. 
.------------+lR .... : .0'0·:. 
plasma Glucose 
Figure B. 1: Simulink schematic diagram showing the top level structure of the 
simulator 
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Figure B.2: Simulink schematic diagram showing the top level of the insulin 
absorption model and the three insulin actions on transport, disposal, and 
suppression. 
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Figure B.3: Simulink schematic diagram showing insulin absorption implemented 
as a function block. 
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scri::r. 
Figure B.4: Simulink schematic diagram showing insulin absorption implemented 
as a function block. 
In1 
Figure B.5: Simulink schematic diagram showing insulin action on disposal 
implemented as a function block. 
In 1 
Figure B.6: Simulink schematic diagram showing insulin action on hepatic 
glucose production implemented as a function block. 
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Figure B.7: Simulink schematic diagram showing gut absorption. 
Figure B.8: Simulink schematic diagram showing fluxes associated with the 
glucose accessible compartment and the non accessible compartment G1 and 
G2. 
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Figure B.9: Simulink schematic diagram showing the calibration procedure. 
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Figure B. 10: Simulink schematic diagram showing saturation process of Fot 
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Figure B. 11: Simulink schematic diagram showing hepatic glucose production. 
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Figure B.12: Simulink schematic diagram showing the top level structure of the 
renal clearance model. 
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Figure B. 13: Simulink schematic diagram showing the renal clearance threshold. 
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Figure B.14: Simulink schematic diagram showing conversIon of amount to 
concentration. 
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Figure B. 15: Simulink schematic diagram showing F01 saturation process. 
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c. Publications 
This appendix contains, an article published in Artificial Intelligence in Medicine, 
Elsevier, and an article published in Diabetes Technology & Therapeutics. 
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